NZ615583B2 - Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease - Google Patents
Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease Download PDFInfo
- Publication number
- NZ615583B2 NZ615583B2 NZ615583A NZ61558312A NZ615583B2 NZ 615583 B2 NZ615583 B2 NZ 615583B2 NZ 615583 A NZ615583 A NZ 615583A NZ 61558312 A NZ61558312 A NZ 61558312A NZ 615583 B2 NZ615583 B2 NZ 615583B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- substituted
- unsubstituted
- group
- alkenyl
- Prior art date
Links
- 206010001897 Alzheimer's disease Diseases 0.000 title claims abstract description 24
- 230000000051 modifying Effects 0.000 title claims abstract description 21
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 title claims abstract description 8
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 title claims abstract description 8
- 206010053643 Neurodegenerative disease Diseases 0.000 title claims description 8
- 206010061536 Parkinson's disease Diseases 0.000 title description 11
- 150000003233 pyrroles Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 129
- -1 polymorphs Substances 0.000 claims abstract description 101
- 239000000203 mixture Substances 0.000 claims abstract description 58
- 201000010099 disease Diseases 0.000 claims abstract description 46
- 239000011780 sodium chloride Substances 0.000 claims abstract description 38
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 239000012453 solvate Substances 0.000 claims abstract description 18
- 206010057668 Cognitive disease Diseases 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 104
- 125000000623 heterocyclic group Chemical group 0.000 claims description 48
- 125000003118 aryl group Chemical group 0.000 claims description 45
- 125000003342 alkenyl group Chemical group 0.000 claims description 44
- 125000000304 alkynyl group Chemical group 0.000 claims description 43
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 35
- 229910052736 halogen Inorganic materials 0.000 claims description 29
- 150000002367 halogens Chemical group 0.000 claims description 29
- 125000001424 substituent group Chemical group 0.000 claims description 29
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 25
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 206010012289 Dementia Diseases 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 23
- 125000004043 oxo group Chemical group O=* 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 230000003287 optical Effects 0.000 claims description 16
- 201000000980 schizophrenia Diseases 0.000 claims description 14
- 208000005765 Traumatic Brain Injury Diseases 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 206010070976 Craniocerebral injury Diseases 0.000 claims description 12
- 150000001204 N-oxides Chemical class 0.000 claims description 11
- YIYZHARUXWKUEN-UHFFFAOYSA-N benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1.NS(=O)(=O)C1=CC=CC=C1 YIYZHARUXWKUEN-UHFFFAOYSA-N 0.000 claims description 11
- 229940079593 drugs Drugs 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 150000003462 sulfoxides Chemical class 0.000 claims description 10
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 125000002950 monocyclic group Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000005842 heteroatoms Chemical group 0.000 claims description 7
- 210000004558 Lewy Bodies Anatomy 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 201000004810 vascular dementia Diseases 0.000 claims description 6
- 230000003405 preventing Effects 0.000 claims description 5
- 229940005513 ANTIDEPRESSANTS Drugs 0.000 claims description 4
- 208000010385 Neurocognitive Disorders Diseases 0.000 claims description 4
- 230000001430 anti-depressive Effects 0.000 claims description 4
- 239000000935 antidepressant agent Substances 0.000 claims description 4
- 229960000074 biopharmaceuticals Drugs 0.000 claims description 4
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 4
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 230000001404 mediated Effects 0.000 claims description 4
- 150000002829 nitrogen Chemical group 0.000 claims description 4
- 125000003003 spiro group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 230000000561 anti-psychotic Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 13
- 230000000069 prophylaxis Effects 0.000 abstract description 12
- 238000002560 therapeutic procedure Methods 0.000 abstract description 9
- 206010039966 Senile dementia Diseases 0.000 abstract description 4
- 239000000651 prodrug Substances 0.000 abstract description 4
- 229940002612 prodrugs Drugs 0.000 abstract description 4
- 239000002207 metabolite Substances 0.000 abstract 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 59
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 description 31
- 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 102000034433 acetylcholine receptors Human genes 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 108020000715 acetylcholine receptors Proteins 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000000556 agonist Substances 0.000 description 13
- 208000002193 Pain Diseases 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 238000007792 addition Methods 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 230000001149 cognitive Effects 0.000 description 10
- 230000015654 memory Effects 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000002829 reduced Effects 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 7
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000003935 attention Effects 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 230000001713 cholinergic Effects 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- 206010065040 AIDS dementia complex Diseases 0.000 description 6
- 229960004373 Acetylcholine Drugs 0.000 description 6
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 6
- 201000006287 attention deficit hyperactivity disease Diseases 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 210000004027 cells Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 230000001537 neural Effects 0.000 description 6
- 210000000056 organs Anatomy 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 206010003246 Arthritis Diseases 0.000 description 5
- 210000004556 Brain Anatomy 0.000 description 5
- 206010067889 Dementia with Lewy body Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 201000002832 Lewy body dementia Diseases 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- 230000001154 acute Effects 0.000 description 5
- 125000005907 alkyl ester group Chemical group 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000001225 therapeutic Effects 0.000 description 5
- RVLWYJGGNGVULN-UHFFFAOYSA-N 1,2-dihydrobenzotriazol-4-one;hydrate Chemical compound O.O=C1C=CC=C2NNN=C12 RVLWYJGGNGVULN-UHFFFAOYSA-N 0.000 description 4
- BSXPDVKSFWQFRT-UHFFFAOYSA-N 1-hydroxytriazolo[4,5-b]pyridine Chemical compound C1=CC=C2N(O)N=NC2=N1 BSXPDVKSFWQFRT-UHFFFAOYSA-N 0.000 description 4
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- 210000004204 Blood Vessels Anatomy 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- ORTQZVOHEJQUHG-UHFFFAOYSA-L Copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 206010013663 Drug dependence Diseases 0.000 description 4
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 4
- 206010021425 Immune system disease Diseases 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 229940047122 Interleukins Drugs 0.000 description 4
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 4
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Substances ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Substances BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 208000004296 Neuralgia Diseases 0.000 description 4
- BKIMMITUMNQMOS-UHFFFAOYSA-N Nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 4
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 4
- 206010036376 Post herpetic neuralgia Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 4
- 229960004793 Sucrose Drugs 0.000 description 4
- CZDYPVPMEAXLPK-UHFFFAOYSA-N Tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 4
- 210000004515 Ventral Tegmental Area Anatomy 0.000 description 4
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 4
- 125000004429 atoms Chemical group 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000019771 cognition Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000008389 polyethoxylated castor oil Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 208000005298 Acute Pain Diseases 0.000 description 3
- 206010004938 Bipolar disease Diseases 0.000 description 3
- 210000003169 Central Nervous System Anatomy 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 206010011401 Crohn's disease Diseases 0.000 description 3
- 201000010374 Down syndrome Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 201000001971 Huntington's disease Diseases 0.000 description 3
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 3
- 229960002715 Nicotine Drugs 0.000 description 3
- 206010057852 Nicotine dependence Diseases 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 3
- 201000011585 Pick's disease Diseases 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 208000004550 Postoperative Pain Diseases 0.000 description 3
- 208000000399 Procedural Pain Diseases 0.000 description 3
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 3
- 206010040070 Septic shock Diseases 0.000 description 3
- 210000003491 Skin Anatomy 0.000 description 3
- 206010044248 Toxic shock syndrome Diseases 0.000 description 3
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 3
- 206010044688 Trisomy 21 Diseases 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 230000003281 allosteric Effects 0.000 description 3
- 102000019082 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 description 3
- 108010051895 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000003110 anti-inflammatory Effects 0.000 description 3
- 239000003693 atypical antipsychotic agent Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 230000001684 chronic Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 201000011240 frontotemporal dementia Diseases 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000005658 halogenation reaction Methods 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229930015196 nicotine Natural products 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 230000002335 preservative Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001953 sensory Effects 0.000 description 3
- 230000036303 septic shock Effects 0.000 description 3
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000005062 synaptic transmission Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 201000006704 ulcerative colitis Diseases 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 208000008811 Agoraphobia Diseases 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 206010002556 Ankylosing spondylitis Diseases 0.000 description 2
- 102100012389 CHRNA7 Human genes 0.000 description 2
- 101710006070 CHRNA7 Proteins 0.000 description 2
- 206010009839 Coeliac disease Diseases 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L Copper(II) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000012593 Hanks’ Balanced Salt Solution Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 229960001375 Lactose Drugs 0.000 description 2
- 210000004940 Nucleus Anatomy 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene (PE) Substances 0.000 description 2
- 208000002389 Pouchitis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N Scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 206010053879 Sepsis syndrome Diseases 0.000 description 2
- 206010040535 Shared psychotic disease Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- JKEKMBGUVUKMQB-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JKEKMBGUVUKMQB-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000003502 anti-nociceptive Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 229960003280 cupric chloride Drugs 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;N-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 125000005945 imidazopyridyl group Chemical group 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000013016 learning Effects 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 210000002569 neurons Anatomy 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 239000008180 pharmaceutical surfactant Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000006977 prepulse inhibition Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000750 progressive Effects 0.000 description 2
- 230000002633 protecting Effects 0.000 description 2
- 201000004681 psoriasis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 230000005586 smoking cessation Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 230000000989 vascularization Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YNBXNVUZXFMNSJ-UHFFFAOYSA-N (4-bromophenyl) 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate;hydrochloride Chemical compound Cl.C1=CC(Br)=CC=C1OC(=O)N1C(CC2)CCN2CC1 YNBXNVUZXFMNSJ-UHFFFAOYSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-Trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- ILWJAOPQHOZXAN-UHFFFAOYSA-N 1,3-dithianyl Chemical group [CH]1SCCCS1 ILWJAOPQHOZXAN-UHFFFAOYSA-N 0.000 description 1
- FLOJNXXFMHCMMR-UHFFFAOYSA-N 1,3-dithiolanyl Chemical group [CH]1SCCS1 FLOJNXXFMHCMMR-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- HWIVGBQUEUPWHG-UHFFFAOYSA-N 1-thia-2,3-diazacyclopent-2-en-4-yne Chemical group S1N=NC#C1 HWIVGBQUEUPWHG-UHFFFAOYSA-N 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N 2,3-dihydro-1H-indole Chemical group C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- XNLICIUVMPYHGG-UHFFFAOYSA-N 2-Pentanone Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-L 2-sulfobutanedioate Chemical class OS(=O)(=O)C(C([O-])=O)CC([O-])=O ULUAUXLGCMPNKK-UHFFFAOYSA-L 0.000 description 1
- YZYQQJHFYIVWPS-UHFFFAOYSA-N 3,4,5,6-tetradehydrothiopyran Chemical group [CH]1SC#CC#C1 YZYQQJHFYIVWPS-UHFFFAOYSA-N 0.000 description 1
- BXKYFUGAAFLYJL-BXGYHSFXSA-N 3-[(5E)-5-[(2,4-dimethoxyphenyl)methylidene]-3,4-dihydro-2H-pyridin-6-yl]pyridine;dihydrochloride Chemical compound Cl.Cl.COC1=CC(OC)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 BXKYFUGAAFLYJL-BXGYHSFXSA-N 0.000 description 1
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- NFCBJBRKGMVOAN-IYBDPMFKSA-N 4-[2-(4-chlorophenyl)-4-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-3,5-dimethylpyrrol-1-yl]benzenesulfonamide Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(=O)C1=C(C)N(C=2C=CC(=CC=2)S(N)(=O)=O)C(C=2C=CC(Cl)=CC=2)=C1C NFCBJBRKGMVOAN-IYBDPMFKSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- AXSJIKCPWZKWOG-UHFFFAOYSA-N 5-(4-chlorophenyl)-2,4-dimethyl-1-(4-sulfamoylphenyl)pyrrole-3-carboxylic acid Chemical compound CC=1C(C(O)=O)=C(C)N(C=2C=CC(=CC=2)S(N)(=O)=O)C=1C1=CC=C(Cl)C=C1 AXSJIKCPWZKWOG-UHFFFAOYSA-N 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N 5-(7-(4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 206010001954 Amnestic disease Diseases 0.000 description 1
- 229940025084 Amphetamine Drugs 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000003455 Anaphylaxis Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 206010057666 Anxiety disease Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 240000005781 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 210000003403 Autonomic Nervous System Anatomy 0.000 description 1
- 102100013894 BCL2 Human genes 0.000 description 1
- 108060000885 BCL2 Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 210000000133 Brain Stem Anatomy 0.000 description 1
- 206010006360 Brief psychotic disease Diseases 0.000 description 1
- CODNYICXDISAEA-UHFFFAOYSA-N Bromine monochloride Chemical compound BrCl CODNYICXDISAEA-UHFFFAOYSA-N 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N Bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- MOTHUBJOUGRFPE-UHFFFAOYSA-N C12CC2CCCC21CCCC2 Chemical compound C12CC2CCCC21CCCC2 MOTHUBJOUGRFPE-UHFFFAOYSA-N 0.000 description 1
- KADZWYHUUBXOPO-UHFFFAOYSA-N C1CC11C2CCCC2CC1 Chemical compound C1CC11C2CCCC2CC1 KADZWYHUUBXOPO-UHFFFAOYSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 206010058019 Cancer pain Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 210000003710 Cerebral Cortex Anatomy 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N Chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 208000010247 Contact Dermatitis Diseases 0.000 description 1
- 208000008208 Craniocerebral Trauma Diseases 0.000 description 1
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N Cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 206010012256 Delusional disease Diseases 0.000 description 1
- 206010061811 Demyelinating polyneuropathy Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N Dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013982 Dysthymic disease Diseases 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 206010067410 Endotoxaemia Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- RPYWXZCFYPVCNQ-UHFFFAOYSA-N GTS-21 Chemical compound COC1=CC(OC)=CC=C1C=C1C(C=2C=NC=CC=2)=NCCC1 RPYWXZCFYPVCNQ-UHFFFAOYSA-N 0.000 description 1
- 210000003192 Ganglia, Autonomic Anatomy 0.000 description 1
- 206010018075 Generalised anxiety disease Diseases 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000002183 Guillain-Barre Syndrome Diseases 0.000 description 1
- 102000000849 HMGB Proteins Human genes 0.000 description 1
- 108010001860 HMGB Proteins Proteins 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 210000003494 Hepatocytes Anatomy 0.000 description 1
- 208000007514 Herpes Zoster Diseases 0.000 description 1
- 208000006213 Herpesviridae Infection Diseases 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N Hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 210000001320 Hippocampus Anatomy 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 208000003532 Hypothyroidism Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000009856 Lung Disease Diseases 0.000 description 1
- 206010025169 Lyme disease Diseases 0.000 description 1
- 210000003563 Lymphoid Tissue Anatomy 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940050176 Methyl Chloride Drugs 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000010076 Mononeuropathy Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- KADXVMRYQRCLAH-UHFFFAOYSA-N N'-iodobutanediamide Chemical compound NC(=O)CCC(=O)NI KADXVMRYQRCLAH-UHFFFAOYSA-N 0.000 description 1
- WECKJONDRAUFDD-ZDUSSCGKSA-N N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-4-chlorobenzamide Chemical compound C1=CC(Cl)=CC=C1C(=O)N[C@@H]1C(CC2)CCN2C1 WECKJONDRAUFDD-ZDUSSCGKSA-N 0.000 description 1
- SSRDSYXGYPJKRR-ZDUSSCGKSA-N N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-1-benzothiophene-2-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC(C=CC=C2Cl)=C2S1 SSRDSYXGYPJKRR-ZDUSSCGKSA-N 0.000 description 1
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 1
- 210000000715 Neuromuscular Junction Anatomy 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N Octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102100001279 PAM Human genes 0.000 description 1
- CEIIEALEIHQDBX-UHFFFAOYSA-N PNU-120,596 Chemical compound C1=C(Cl)C(OC)=CC(OC)=C1NC(=O)NC1=NOC(C)=C1 CEIIEALEIHQDBX-UHFFFAOYSA-N 0.000 description 1
- 206010033666 Panic disease Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010033869 Paranoid personality disease Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229940066842 Petrolatum Drugs 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000004358 Polyneuropathy Diseases 0.000 description 1
- 208000010366 Postpoliomyelitis Syndrome Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000003055 Prion Disease Diseases 0.000 description 1
- 206010061920 Psychotic disease Diseases 0.000 description 1
- VIAFLMPQBHAMLI-UHFFFAOYSA-N PyBOP Chemical compound F[P-](F)(F)(F)(F)F.C1CCCN1[P+](N1CCCC1)(N1CCCC1)ON1C2=CC=CC=C2N=N1 VIAFLMPQBHAMLI-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010039083 Rhinitis Diseases 0.000 description 1
- 206010039624 Schizoid personality disease Diseases 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 240000003670 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 208000007929 Shared Paranoid Disorder Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 208000002320 Spinal Muscular Atrophy Diseases 0.000 description 1
- CTDQAGUNKPRERK-UHFFFAOYSA-N Spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000000225 Synapses Anatomy 0.000 description 1
- 208000006379 Syphilis Diseases 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N Tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N Thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 206010044126 Tourette's disease Diseases 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N Varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 206010047627 Vitamin deficiency Diseases 0.000 description 1
- XCHIZTUBUXZESJ-UHFFFAOYSA-N WAY-317,538 Chemical compound C=1C=C(C=2C=NC=CC=2)C=CC=1NC(=O)CCCCN1CCOCC1 XCHIZTUBUXZESJ-UHFFFAOYSA-N 0.000 description 1
- 201000005634 Werdnig-Hoffmann disease Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- NWGKJDSIEKMTRX-HSACVWGTSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-HSACVWGTSA-N 0.000 description 1
- MVLQNYDTDVNQKJ-UHFFFAOYSA-N [2H-benzotriazol-4-yloxy(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CN(C)C(=[N+](C)C)OC1=CC=CC2=C1N=NN2 MVLQNYDTDVNQKJ-UHFFFAOYSA-N 0.000 description 1
- BIABKPAXSLKGLN-UHFFFAOYSA-N [dimethylamino(2H-triazolo[4,5-b]pyridin-7-yloxy)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CN(C)C(=[N+](C)C)OC1=CC=NC2=C1N=NN2 BIABKPAXSLKGLN-UHFFFAOYSA-N 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229960002734 amfetamine Drugs 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000002424 anti-apoptotic Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical group C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- JAPMJSVZDUYFKL-UHFFFAOYSA-N bicyclo[3.1.0]hexane Chemical group C1CCC2CC21 JAPMJSVZDUYFKL-UHFFFAOYSA-N 0.000 description 1
- SHOMMGQAMRXRRK-UHFFFAOYSA-N bicyclo[3.1.1]heptane Chemical group C1C2CC1CCC2 SHOMMGQAMRXRRK-UHFFFAOYSA-N 0.000 description 1
- AWYMFBJJKFTCFO-UHFFFAOYSA-N bicyclo[3.2.0]heptane Chemical class C1CCC2CCC21 AWYMFBJJKFTCFO-UHFFFAOYSA-N 0.000 description 1
- GNTFBMAGLFYMMZ-UHFFFAOYSA-N bicyclo[3.2.2]nonane Chemical group C1CC2CCC1CCC2 GNTFBMAGLFYMMZ-UHFFFAOYSA-N 0.000 description 1
- WNTGVOIBBXFMLR-UHFFFAOYSA-N bicyclo[3.3.1]nonane Chemical group C1CCC2CCCC1C2 WNTGVOIBBXFMLR-UHFFFAOYSA-N 0.000 description 1
- WMRPOCDOMSNXCQ-UHFFFAOYSA-N bicyclo[3.3.2]decane Chemical group C1CCC2CCCC1CC2 WMRPOCDOMSNXCQ-UHFFFAOYSA-N 0.000 description 1
- KVLCIHRZDOKRLK-UHFFFAOYSA-N bicyclo[4.2.1]nonane Chemical group C1C2CCC1CCCC2 KVLCIHRZDOKRLK-UHFFFAOYSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000010816 bone resorption disease Diseases 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229910021386 carbon form Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000037410 cognitive enhancement Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 201000007336 cryptococcosis Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 201000001149 cyclothymic disease Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000080 dermatitis contact Toxicity 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000001804 emulsifying Effects 0.000 description 1
- 230000002346 endotoxic Effects 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- NLPRAJRHRHZCQQ-IVZWLZJFSA-N epibatidine Chemical compound C1=NC(Cl)=CC=C1[C@@H]1[C@H](N2)CC[C@H]2C1 NLPRAJRHRHZCQQ-IVZWLZJFSA-N 0.000 description 1
- SSVFMICWXDVRQN-UHFFFAOYSA-N ethanol;sodium Chemical compound [Na].CCO SSVFMICWXDVRQN-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoked Effects 0.000 description 1
- 230000002964 excitative Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000006529 generalized anxiety disease Diseases 0.000 description 1
- 230000000848 glutamatergic Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- BNRNAKTVFSZAFA-UHFFFAOYSA-N hydrindane Chemical compound C1CCCC2CCCC21 BNRNAKTVFSZAFA-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- FHQRPERTLOUCMP-UHFFFAOYSA-N hydroxyazanide Chemical class O[NH-] FHQRPERTLOUCMP-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000005969 isothiazolinyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000003367 kinetic assay Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004758 lung carcinogenesis Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 201000003895 major depressive disease Diseases 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001343 mnemonic Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003551 muscarinic Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001703 neuroimmune Effects 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 230000000324 neuroprotective Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical group C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- KREXGRSOTUKPLX-UHFFFAOYSA-N octadecanoic acid;zinc Chemical compound [Zn].CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O KREXGRSOTUKPLX-UHFFFAOYSA-N 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000005963 oxadiazolidinyl group Chemical group 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 201000008175 pain disease Diseases 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 201000001552 phobic disease Diseases 0.000 description 1
- KEDPUQKUZHYBGW-UHFFFAOYSA-O phosphanium;hexafluorophosphate Chemical compound [PH4+].F[P-](F)(F)(F)(F)F KEDPUQKUZHYBGW-UHFFFAOYSA-O 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 201000008839 post-traumatic stress disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000003334 potential Effects 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000003449 preventive Effects 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 201000002241 progressive bulbar palsy Diseases 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 201000000196 pseudobulbar palsy Diseases 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000246 remedial Effects 0.000 description 1
- 201000000978 schizoaffective disease Diseases 0.000 description 1
- 201000000261 schizophreniform disease Diseases 0.000 description 1
- 201000010822 schizotypal personality disease Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000031893 sensory processing Effects 0.000 description 1
- 230000000391 smoking Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- FOEYMRPOKBCNCR-UHFFFAOYSA-N spiro[2.5]octane Chemical compound C1CC11CCCCC1 FOEYMRPOKBCNCR-UHFFFAOYSA-N 0.000 description 1
- 201000002661 spondylitis Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000707 stereoselective Effects 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229960001663 sulfanilamide Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000005304 thiadiazolidinyl group Chemical group 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 229960004751 varenicline Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Disclosed is a compound of formula (I) wherein 'a' and R-R are as described herein, as a modulator of nicotinic acetylcholine receptors particularly the ?7 subtype, in a subject in need thereof, as well as analogues, prodrugs, isotopically substituted analogs, metabolites, pharmaceutically acceptable salts, polymorphs, solvates, isomers, clathrates, and co-crystal thereofs, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds and analogues. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like. e salts, polymorphs, solvates, isomers, clathrates, and co-crystal thereofs, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds and analogues. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.
Description
FPAA2865PCT
PYRROLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR
MODULATORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE
DISORDERS SUCH AS ALZHEIMER'S AND PARKINSON'S DISEASE
Field of the Invention:
The present invention is related to novel compounds of the general formula I,
[ ]
SO NH
(I) 2 2
their tautomeric forms, their stereoisomers, their N-oxides, their
pharmaceutically acceptable salts, polymorphs, solvates, optical isomers,
clathrates, co-crystals, combinations with suitable medicament, pharmaceutical
compositions containing them, methods of making of the above compounds,
and their use as nicotinic acetylcholine receptor α7 subunit (α7 nAChR)
modulator.
Background of the invention:
Cholinergic neurotransmission, mediated primarily through the
neurotransmitter acetylcholine (ACh), is a predominant regulator of the
physiological functions of the body via the central and autonomic nervous
system. ACh acts on the synapses of the neurons present in of all the
autonomic ganglia, neuromuscular junctions and the central nervous system.
Two distinct classes of ACh target receptors viz. muscarinic (mAChRs) and the
nicotinic (nAChRs) have been identified in brain, forming a significant
component of receptors carrying its mnemonic and other vital physiological
functions.
Neural nicotinic ACh receptors (NNRs) belong to the class of ligand-gated ion
channels (LGIC) comprising of five subunits (α2-α10, β2-β4) arranged in
heteropentameric (α4β2) or homopertameric (α7) configuration (Paterson D et
FPAA2865PCT
al., Prog. Neurobiol., 2000, 61, 75-111). α4β2 and α7 nAChR constitute the
predominant subtypes expressed in the mammalian brain. α7 nAChR has
attained prominence as a therapeutic target due to its abundant expression in
the learning and memory centers of brain, hippocampus and the cerebral cortex
(Rubboli F et al., Neurochem. Int., 1994, 25, 69-71). Particularly, α7 nAChR is
characterized by a high Ca ion permeability, which is responsible for
neurotransmitter release and consequent modulation of excitatory and
inhibitory neurotransmission (Alkondon M et al., Eur. J. Pharmacol., 2000, 393,
59-67; Dajas-Bailador F et al., Trends Pharmacol. Sci., 2004, 25, 317-324).
Furthermore, high Ca ion influx also has implications on the long-term
potentiation of memory via alterations in gene expression (Bitner RS et al., J.
Neurosci., 2007, 27, 10578-10587; McKay BE et al., Biochem. Pharmacol.,
2007, 74, 1120-1133).
Several recent studies have confirmed the role of α7 nAChR in neural processes
like attention, memory and cognition (Mansvelder HD et al.,
Psychopharmacology (Berl), 2006, 184, 292-305; Chan WK et al.,
Neuropharmacology, 2007, 52, 1641-1649; Young JW et al., Eur.
Neuropsychopharmacol., 2007, 17, 145-155). Gene polymorphisms associated
with the α7 nAChR protein CHRNA7 have been implicated in the genetic
transmission of schizophrenia, related neurophysiological sensory gating deficits
and resultant cognitive impairment (Freedman R et al., Biol. Psychiatry, 1995,
38, 22-33; Tsuang DW et al., Am. J. Med. Genet., 2001, 105, 662-668). Also,
preclinical studies in α 7 nAChR knock-out and anti-sense oligonucleotide
treated mice have demonstrated impaired attention and defective cognition
underscoring the prominent role of α7 nAChR in cognition (Curzon P et al.,
Neurosci. Lett., 2006, 410, 15-19; Young JW et al., Neuropsychopharmacology.,
2004, 29, 891-900). Additionally, pharmacological blockade of α 7 nAChR
impairs memory and its activation enhances same in preclinical rodent models
implicating α7 nAChR as target for cognitive enhancement (Hashimoto K et al.,
Biol. Psychiatry, 2008, 63, 92-97).
Pathological brain function in sensory-deficit disorders has been associated with
nicotinic cholinergic transmission particularly through α7 receptors (Freedman
FPAA2865PCT
R et al., Biol. Psychiatry, 1995, 38, 22-33; Tsuang DW et al., Am. J. Med.
Genet., 2001, 105, 662-668; Carson R et al., Neuromolecular, 2008, Med. 10,
377-384; Leonard S et al., Pharmacol. Biochem. Behav., 2001, 70, 561-570;
Freedman R et al., Curr. Psychiatry Rep., 2003, 5, 155-161; Cannon TD et al.,
Curr. Opin. Psychiatry, 2005, 18, 135-140). A defective pre-attention processing
of sensory information is understood to be the basis of cognitive fragmentation
in schizophrenia and related neuropsychiatric disorders (Leiser SC et al.,
Pharmacol. Ther., 2009, 122, 302-311). Genetic linkage studies have traced
sharing of the α7 gene locus for several affective, attention, anxiety and
psychotic disorders (Leonard S et al., Pharmacol. Biochem. Behav., 2001, 70,
561-570; Suemaru K et al., Nippon Yakurigaku Zasshi, 2002, 119, 295-300).
Perturbations in the cholinergic and glutamatergic homeostasis, has long been
implicated as causative factors for host of neurological disease, including
dementia(s) (Nizri E et al., Drug News Perspect., 2007, 20, 421-429). Dementia
is a severe, progressive, multi-factorial cognitive disorder affecting memory,
attention, language and problem solving. Nicotinic ACh receptor, particularly
the interaction of α7 receptor to αβ is implicated as an up-stream pathogenic
1-42
event in Alzheimer’s disease, a major causative factor for dementia (Wang HY et
al., J. Neurosci., 2009, 29, 10961-10973). Moreover, gene polymorphisms in
CHRNA7 have been implicated in dementia with lewy bodies (DLB) and Pick’s
disease (Feher A et al., Dement. Geriatr. Cogn. Disord., 2009, 28, 56-62).
Disease modification potential of nAChRs particularly the α7 receptor has
application for disease-modification of Alzheimer ’s disease (AD) and Parkinson’s
disease (PD) by enhancing neuron survival and preventing neurodegeneration
(Wang et al. 2009; Nagele RG et al., Neuroscience, 2002, 110, 199-211;
Jeyarasasingam G et al., Neuroscience, 2002, 109, 275-285). Additionally, α7
nAChR induced activation of anti-apoptotic (BCL-2) and anti-inflammatory
pathways in brain could have neuroprotective effects in neurodegenerative
diseases (Marrero MB et al., Brain. Res., 2009, 1256, 1-7). Dopamine containing
neurons of ventral tegmental area (VTA) and laterodorsal tegmental nucleus
(LDT) are known to express nicotinic ACh receptors, particularly α4, α3, β2, β3,
β4 subunits (Kuzmin A et al., Psychopharmacology (Berl), 2009, 203, 99-108).
FPAA2865PCT
Nicotinic ACh receptors, α4β2 and α3β4 have been identified with candidate-
gene approach to have strong mechanistic link for nicotine addiction (Weiss RB
et al., PLoS Genet., 2008, 4, e1000125). α7 nAChR has particularly been
studied for a putative role in cannabis addiction (Solinas M et al., J. Neurosci.,
2007, 27, 5615-5620). Varenicline, a partial agonist at α4β2, has demonstrated
better efficacy in reducing the smoking addiction and relapse prevention in
comparison to buproprion (Ebbert JO et al., Patient. Prefer. Adherence, 2010, 4,
355-362).
Presence of a high-affinity nicotine binding site at α4β2 nAChR, in the
descending inhibitory pathways from brainstem has sparked interest in the
antinociceptive properties of nicotinic ACh receptor agonists like epibatidine
(Decker MW et al., Expert. Opin. Investig. Drugs, 2001, 10, 1819-1830). Several
new developments have opened the area for use of nicotinic modulators for
therapy of pain (Rowbotham MC et al., Pain, 2009, 146, 245-252). Appropriate
modulation of the nicotinic ACh receptors could provide for remedial approach
to pain related states.
Another key role of the α7 nAChR is the ability to modulate the production of
pro-inflammatory cytokines, like interleukins (IL), tumor necrosis factor alpha
(TNF-α), and high mobility group box (HMGB-1) in the central nervous system.
Consequently, an anti-inflammatory and antinociceptive effect in pain disorders
have been demonstrated (Damaj MI et al., Neuropharmacology, 2000, 39, 2785-
2791). Additionally, ‘cholinergic anti-inflammatory pathway’ is proposed to be a
regulatory of local and systemic inflammation and neuro-immune interactions
through neural and humoral pathways (Gallowitsch-Puerta M et al., Life Sci.,
2007, 80, 2325-2329; Gallowitsch-Puerta and Pavlov 2007; Rosas-Ballina M et
al., Mol. Med., 2009, 15, 195-202; Rosas-Ballina M et al., J. Intern. Med., 2009,
265, 663-679). Selective modulators of nicotinic ACh receptors, particularly α7
type, like GTS-21, attenuate cytokine production and IL-1β after endotoxin
exposure. Furthermore, α7 nAChR are understood to have a central role in
arthritis pathogenesis and potential therapeutic strategy for treatment of joint
inflammation (Westman M et al., Scand. J. Immunol., 2009, 70, 136-140). A
FPAA2865PCT
putative role for α7 nAChR has also been implicated in severe sepsis,
endotoxemic shock and systemic inflammation (Jin Y et al. (2010) Int. J.
Immunogenet., Liu C et al., Crit. Care. Med., 2009, 37, 634-641).
Angiogenesis, is a critical physiological process for the cell survival and
pathologically important for cancer proliferation; several non-neural nicotinic
ACh receptors, particularly α7, α5, α3, β2, β4, are involved (Arias HR et al., Int.
J. Biochem. Cell. Biol., 2009, 41, 1441-1451; Heeschen C et al., J. Clin. Invest.,
2002, 110, 527-536). A role of nicotinic ACh receptors in the development of
cervical cancer, lung carcinogenesis and paediatric lung disorders in smoking-
exposed population has also been studied (Calleja-Macias IE et al., Int. J.
Cancer., 2009, 124, 1090-1096; Schuller HM et al., Eur. J. Pharmacol., 2000,
393, 265-277). Several α7 nAChR agonists, partial agonists, have been
characterized for their efficacy in clinical and preclinical studies. EVP-6124, an
agonist at α7 nAChR, has demonstrated significant improvement in sensory
processing and cognition biomarkers in Phase Ib study with patients suffering
from schizophrenia (EnVivo Pharmaceuticals press release 2009, Jan 12). GTS-
21 (DMXB-Anabaseine), an α7 nAChR agonist, in the P II clinical trials, has
shown efficacy in improving cognitive deficits in schizophrenia and inhibition of
endotoxin-induced TNF-α release (Olincy A et al., Biol. Psychiatry, 2005, 57(8,
Suppl.), Abst 44; Olincy A et al., Arch. Gen. Psychiatry, 2006, 63, 630-638;
Goldstein R et al., Acad. Emerg. Med., 2007, 14 (15, Suppl. 1), Abst 474). CP-
810123, a α7 nAChR agonist, exhibits protection against the scopolamine-
induced dementia and inhibition of amphetamine-induced auditory evoked
potentials in preclinical studies (O'Donnell CJ et al., J. Med. Chem., 2010, 53,
1222-1237). SSR-180711A, also an α7 nAChR agonist, enhances learning and
memory, and protects against MK-801/Scopolamine-induced memory loss and
prepulse inhibition in preclinical studies (Redrobe JP et al., Eur. J. Pharmacol.,
2009, 602, 58-65; Dunlop J et al., J. Pharmacol. Exp. Ther., 2009, 328, 766-
776; Pichat P et al., Neuropsychopharmacology, 2007, 32, 17-34). SEN-12333,
protected against scopolamine-induced amnesia in passive avoidance test in
preclinical studies (Roncarati R et al., J. Pharmacol. Exp. Ther., 2009, 329, 459-
468). AR-R-17779, an agonist at α7 nAChR, exhibits improvement in the social
recognition task performed in rats (Van KM et al., Psychopharmacology (Berl),
FPAA2865PCT
2004, 172, 375-383). ABBF, an agonist at α7 nAChR, improves social
recognition memory and working memory in Morris maze task in rats (Boess FG
et al., J. Pharmacol. Exp. Ther., 2007, 321, 716-725). TC-5619, a selective α7
nAChR agonist has demonstrated efficacy in animal models of positive and
negative symptoms and cognitive dysfunction in schizophrenia (Hauser TA et
al., Biochem. Pharmacol., 2009, 78, 803-812).
An alternative strategy to reinforce or potentiate the endogenous cholinergic
neurotransmission of ACh without directly stimulating the target receptor is the
positive allosteric modulation (PAM) of α7 nAChR (Albuquerque EX et al.,
Alzheimer Dis. Assoc. Disord., 2001, 15 Suppl 1, S19-S25). Several PAMs have
been characterized, albeit in the preclinical stages of discovery. A-86774, α7
nAChR PAM, improves sensory gating in DBA/2 mice by significantly reducing
the T:C ratio in a preclinical model of schizophrenia (Faghih R et al., J. Med.
Chem., 2009, 52, 3377-3384). XY-4083, an α7 nAChR PAM, normalizes the
sensorimotor gating deficits in the DBA/2 mice and memory acquisition in 8-
arm radial maze without altering the receptor desensitization kinetics (Ng HJ et
al., Proc. Natl. Acad. Sci., U. S. A., 2007, 104, 8059-8064). Yet another PAM,
PNU-120596, profoundly alters α7 nAChR desensitization kinetics and
simultaneously protecting against the disruption of prepulse inhibition by MK-
801. NS-1738, another PAM, has exhibited efficacy in-vivo in the animal models
of social recognition and spatial memory acquisition in the Morris maze task
(Timmermann DB et al., J. Pharmacol. Exp. Ther., 2007, 323, 294-307). In
addition, several patents/applications published are listed below -
US20060142349, US20070142450, US20090253691, WO2007031440,
WO2009115547, WO2009135944, WO2009127678, WO2009127679,
WO2009043780, WO2009043784, US7683084, US7741364, WO2009145996,
US20100240707, WO2011064288, US20100222398, US20100227869,
EP1866314, WO2010130768, WO2011036167, US20100190819 disclose
efficacy of allosteric modulators of nicotinic ACh receptors and underscoring
their therapeutic potential.
Summary of the Invention
FPAA2865PCT
Acccording to one aspect of the present invention there is provided compounds
represented by the general formula I, its tautomeric forms, its stereoisomers, its
pharmaceutically acceptable salts, its polymorphs, its solvates, its optical
isomers, its clathrates, its co-crystals, their combinations with suitable
medicament and pharmaceutical compositions containing them.
Thus the present invention further provides a pharmaceutical composition,
containing the compounds of the general formula (I) as defined herein, its
tautomeric forms, its stereoisomers, its pharmaceutically acceptable salts, its
polymorphs, its solvates, its optical isomers, its clathrates and its co-crystals in
combination with the usual pharmaceutically employed carriers, diluents and
the like are useful for the treatment and/or prophylaxis of diseases or disorder
or condition such as Alzheimer's disease (AD), mild cognitive impairment (MCI),
senile dementia, vascular dementia, dementia of Parkinson’s disease, attention
deficit disorder, attention deficit hyperactivity disorder (ADHD), dementia
associated with Lewy bodies, AIDS dementia complex (ADC), Pick's disease,
dementia associated with Down's syndrome, Huntington's disease, cognitive
deficits associated with traumatic brain injury (TBI), cognitive decline associated
with stroke, poststroke neuroprotection, cognitive and sensorimotor gating
deficits associated with schizophrenia, cognitive deficits associated with bipolar
disorder, cognitive impairments associated with depression, acute pain, post-
surgical or post-operative pain, chronic pain, inflammation, inflammatory pain,
neuropathic pain, smoking cessation, need for new blood vessel growth
associated with wound healing, need for new blood vessel growth associated
with vascularization of skin grafts, and lack of circulation, arthritis, rheumatoid
arthritis, psoriasis, Crohn's disease, ulcerative colitis, pouchitis, inflammatory
bowel disease, celiac disease, periodontitis, sarcoidosis, pancreatitis, organ
transplant rejection, acute immune disease associated with organ
transplantation, chronic immune disease associated with organ transplantation,
septic shock, toxic shock syndrome, sepsis syndrome, depression, and
rheumatoid spondylitis.
The present invention also provides a pharmaceutical composition, containing
the compounds of the general formula (I) as defined herein, its tautomeric
FPAA2865PCT
forms, its stereoisomers, its pharmaceutically acceptable salts, its polymorphs,
its solvates, its optical isomers, its clathrates and its co-crystals in combination
with the usual pharmaceutically employed carriers, diluents and the like are
useful for the treatment and/or prophylaxis of diseases or disorder or condition
classified or diagnosed as major or minor neurocognitive disorders, or disorders
arising due to neurodegeneration.
Also described herein is a method of administering a compound of formula I, as
defined herein in combination with or as adjunct to medications used in the
treatment of attention deficit hyperactivity disorders, schizophrenia, and other
cognitive disorders such as Alzheimer's disease, Parkinson’s dementia, vascular
dementia or dementia associated with Lewy bodies, traumatic brain injury.
Also described herein is a method of administering a compound of formula I, as
defined herein in combination with or as an adjunct to acetylcholinesterase
inhibitors, disease modifying drugs or biologics for neurodegenerative disorders,
dopaminergic drugs, antidepressants, typical or an atypical antipsychotic.
The present invention also provides use of a compound of formula I as defined
herein in the preparation of a medicament for treating a disease or disorder or
condition selected from the group classified or diagnosed as major or minor
neurocognitive disorders, or disorders arising due to neurodegeneration.
The present invention also provides use of a compound of formula I as defined
herein in the preparation of a medicament for treating a disease or disorder or
condition selected from the group consisting of attention deficit hyperactivity
disorders, schizophrenia, cognitive disorders, Alzheimer's disease, Parkinson’s
dementia, vascular dementia or dementia associated with Lewy bodies, and
traumatic brain injury.
The present invention also provides use of compound of formula I as defined
herein in combination with or as an adjunct to acetylcholinesterase inhibitors,
FPAA2865PCT
disease modifying drugs or biologics for neurodegenerative disorders,
dopaminergic drugs, antidepressants, or a typical or atypical antipsychotic.
Detailed Description of the invention:
The present invention relates to novel compounds of the general formula I, its
tautomeric forms, its stereoisomers, its sulfoxides, its N-oxides, its
pharmaceutically acceptable salts, its polymorphs, its solvates, its optical
isomers, its clathrates, its co-crystals, their combinations with suitable
medicament and pharmaceutical compositions containing them.
[ ]
SO NH
(I) 2 2
wherein,
R is selected from the group consisting of hydrogen, halogen, substituted- or
unsubstituted- alkyl, substituted- or unsubstituted- alkenyl, substituted- or
unsubstituted- alkynyl, perhaloalkyl, and substituted- or unsubstituted-
cycloalkyl;
R is selected from the group consisting of substituted- or unsubstituted- alkyl,
6 7 6 7a 6a
(R )(R )N-, (R )N(OR )-, and R O-;
R is selected from the group consisting of substituted- or unsubstituted- alkyl,
substituted- or unsubstituted- alkenyl, substituted- or unsubstituted- alkynyl,
substituted- or unsubstituted- cycloalkyl;
R is selected from the group consisting of substituted- or unsubstituted- aryl,
substituted- or unsubstituted- heteroaryl;
FPAA2865PCT
5 5
[R ] is ‘a’ times repetition of ‘R ’ groups, each R is independently selected from
the group consisting of halo, substituted- or unsubstituted- alkyl, R O-; ‘a’ is an
integer selected from 0, 1, and 2;
wherein, R and R are independently selected from hydrogen, substituted- or
9 9 2 6 7 6
unsubstituted- alkyl, R C(=O)-, R SO -; such that when R is (R )(R )N-, R and
R together with the nitrogen atom to which they are attached may form a 3 to
member substituted- or unsubstituted- heterocycle containing one to three
hetero atoms/groups selected from the group consisting of S, N, O the said
heterocycle may be saturated or unsaturated, monocyclic or bicyclic or spiro, or
the said heterocycle may contain an alkylene bridge;
R is selected from hydrogen and substituted- or unsubstituted- alkyl;
R is selected as substituted- or unsubstituted- alkyl;
wherein R is selected from hydrogen, substituted- or unsubstituted- alkyl, and
perhaloalkyl;
wherein, R is independently selected from the group consisting of hydrogen,
substituted- or unsubstituted- alkyl, substituted- or unsubstituted- aryl,
substituted- or unsubstituted- heteroaryl, substituted- or unsubstituted-
cycloalkyl, and substituted- or unsubstituted- heterocyclyl;
wherein,
the “alkyl", “alkenyl", and “alkynyl" are substituted with 1 to 6 substituents
selected independently from the group consisting of oxo, halogen, nitro, cyano,
10a 10 1 10a 10a
aryl, hereroaryl, cycloalkyl, R SO -, R A -, R OC(=O)-, R C(=O)O-,
10 10a 10 10
(R )(H)NC(=O)-, (R )(alkyl)NC(=O)-, R C(=O)N(H)-, (R )(H)N-, (R )(alkyl)N-,
1 10 1
(R )(H)NC(=A )N(H)-, and (R )(alkyl)NC(=A )N(H)-;
the “cycloalkyl" is substituted with 1 to 6 substituents selected independently
from the group consisting of oxo, halogen, nitro, cyano, aryl, hereroaryl, alkyl,
10a 10a 10 1 10a 10a
alkenyl, alkynyl, R C(=O)-, R SO -, R A -, R OC(=O)-, R C(=O)O-,
10 10a 10 10
(R )(H)NC(=O)-, (R )(alkyl)NC(=O)-, R C(=O)N(H)-, (R )(H)N-, (R )(alkyl)N-,
1 10 1
(R )(H)NC(=A )N(H)-, and (R )(alkyl)NC(=A )N(H)-;
FPAA2865PCT
the "aryl" is substituted with 1 to 3 substituents selected independently from
the group consisting of halogen, nitro, cyano, hydroxy, C to C alkyl, C to C
1 6 2 6
alkenyl, C to C alkynyl, C to C cycloalkyl, 3- to 6- membered heterocycle, C
2 6 3 6 1
to C perhaloalkyl, alkyl-O-, alkenyl-O-, alkynyl-O-, perhaloalkyl-O-, alkyl-
N(alkyl)-, alkyl-N(H)-, H N-, alkyl-SO -, perhaloalkyl-SO -, alkyl-C(=O)N(alkyl)-,
2 2 2
alkyl-C(=O)N(H)-, alkyl-N(alkyl)C(=O)-, alkyl-N(H)C(=O)-, H NC(=O)-, alkyl-
N(alkyl)SO -, alkyl-N(H)SO -, H NSO -;
2 2 2 2
the “heterocyclyl" is substituted on ring carbons with 1 to 6 substituents
selected independently from the group consisting of oxo, halogen, nitro, cyano,
1 10a 10a
aryl, hereroaryl, alkyl, alkenyl, alkynyl, R A -, R OC(=O)-, R C(=O)O-,
10 10a 10 10
(R )(H)NC(=O)-, (R )(alkyl)NC(O)-, R C(=O)N(H)-, (R )(H)N-, (R )(alkyl)N-,
1 10 1
(R )(H)NC(=A )N(H)-, and (R )(alkyl)NC(=A )N(H)-;
the “heterocyclyl” is substituted on ring nitrogen(s) with one or more
substituents selected from the group consisting of aryl, hereroaryl, alkyl,
10a 10a 10a 10
alkenyl, alkynyl, R C(=O)-, R SO -, R OC(=O)-, (R )(H)NC(=O)-,
(R )(alkyl)NC(=O)-;
the "heteroaryl" is substituted with 1 to 3 substituents selected independently
from the group consisting of halogen, nitro, cyano, hydroxy, C1 to C6 alkyl, C2
to C alkenyl, C to C alkynyl, C to C cycloalkyl, 3- to 6- membered
6 2 6 3 6
heterocycle, C to C perhaloalkyl, alkyl-O-, alkenyl-O-, alkynyl-O-,
perhaloalkyl-O-, alkyl-N(alkyl)-, alkyl-N(H)-, H N-, alkyl-SO -, perhaloalkyl-SO -,
2 2 2
alkyl-C(=O)N(alkyl)-, alkyl-C(=O)N(H)-, alkyl-N(alkyl)C(=O)-, alkyl-N(H)C(=O)-,
H NC(=O)-, alkyl-N(alkyl)SO -, and alkyl-N(H)SO -, H NSO -;
2 2 2 2 2
the “3- to 10- membered heterocyclic ring” is substituted with 1 to 3
substituents selected from the group consisting of oxo, halogen, nitro, cyano,
10a 10a 10 1 10a
aryl, hereroaryl, alkyl, alkenyl, alkynyl, R C(=O)-, R SO -, R A -, R OC(=O)-
10a 10 10 10a 10
, R C(=O)O-, (R )(H)NC(=O)-, (R )(alkyl)NC(=O)-, R C(=O)N(H)-, (R )(H)N-,
10 1 10 1
(R )(alkyl)N-, (R )(H)NC(=A )N(H)-, and (R )(alkyl)NC(=A )N(H)-;
wherein,
A is selected from the group consisting of O and S;
FPAA2865PCT
R is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl
or heterocyclyl; and
R is selected from the group consisting of alkyl, alkenyl, alkynyl, perhaloalkyl,
aryl, heteroaryl, cycloalkyl or heterocyclyl.
Whenever a range of the number of atoms in a structure is indicated (e.g., a C
, C , C , or C alkyl, alkylamino, etc.), it is specifically contemplated that
12 1-8 1-6 1-4
any sub-range or individual number of carbon atoms falling within the indicated
range also can be used. Thus, for instance, the recitation of a range of 1-8
carbon atoms (e.g., C -C ), 1-6 carbon atoms (e.g., C -C ), 1-4 carbon atoms
1 8 1 6
(e.g., C1-C4), 1-3 carbon atoms (e.g., C1-C3), or 2-8 carbon atoms (e.g., C2-C8) as
used with respect to any chemical group (e.g., alkyl, alkylamino, etc.) referenced
herein encompasses and specifically describes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
and/or 12 carbon atoms, as appropriate, as well as any sub-range thereof (e.g.,
1-2 carbon atoms, 1-3 carbon atoms, 1-4 carbon atoms, 1-5 carbon atoms, 1-6
carbon atoms, 1-7 carbon atoms, 1-8 carbon atoms, 1-9 carbon atoms, 1-10
carbon atoms, 1-11 carbon atoms, 1-12 carbon atoms, 2-3 carbon atoms, 2-4
carbon atoms, 2-5 carbon atoms, 2-6 carbon atoms, 2-7 carbon atoms, 2-8
carbon atoms, 2-9 carbon atoms, 2-10 carbon atoms, 2-11 carbon atoms, 2-12
carbon atoms, 3-4 carbon atoms, 3-5 carbon atoms, 3-6 carbon atoms, 3-7
carbon atoms, 3-8 carbon atoms, 3-9 carbon atoms, 3-10 carbon atoms, 3-11
carbon atoms, 3-12 carbon atoms, 4-5 carbon atoms, 4-6 carbon atoms, 4-7
carbon atoms, 4-8 carbon atoms, 4-9 carbon atoms, 4-10 carbon atoms, 4-11
carbon atoms, and/or 4-12 carbon atoms, etc., as appropriate).
In one of the embodiments of the invention described above, R is preferably
selected as substituted- or unsubstituted- alkyl.
In any of the embodiments described above, R is preferably selected as
substituted- or unsubstituted- alkyl.
In any of the embodiments described above, R is preferably selected as
substituted- or unsubstituted- alkyl.
In any of the embodiments described above, R is preferably selected as
substituted- or unsubstituted- aryl.
FPAA2865PCT
In any of the embodiments described above, ‘a’ is preferably selected as 0.
In any of the embodiments described above, R is preferably selected as
substituted- or unsubstituted- alkyl; R is preferably selected as substituted- or
unsubstituted- alkyl; R is preferably selected as substituted- or unsubstituted-
alkyl; R is preferably selected as substituted- or unsubstituted- aryl; and ‘a’ is
preferably selected as 0.
General terms used in formula can be defined as follows; however, the meaning
stated should not be interpreted as limiting the scope of the term per se.
The term "alkyl", as used herein, means a straight chain or branched
hydrocarbon containing from 1 to 20 carbon atoms. Preferably the alkyl chain
may contain 1 to 10 carbon atoms. More preferably alkyl chain may contain up
to 6 carbon atoms. Representative examples of alkyl include, but are not limited
to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl,
n-pentyl, isopentyl, neopentyl, and n-hexyl.
The term “alkenyl” as used herein, means an ‘alkyl’ group as defined
hereinabove containing 2 to 20 carbon atoms and containing at least one double
bond.
The term “alkynyl” as used herein, means an ‘alkyl’ group as defined
hereinabove containing 2 to 20 carbon atoms and containing at least one triple
bond.
‘Alkyl’, ‘alkenyl’ or ‘alkynyl’ as defined hereinabove may be substituted with one
or more substituents selected independently from the group comprising of oxo,
10a 10 1 10a
halogen, nitro, cyano, aryl, hereroaryl, cycloalkyl, R SO -, R A -, R OC(=O)-,
10a 10 10 10a 10
R C(=O)O-, (R )(H)NC(=O)-, (R )(alkyl)NC(=O)-, R C(=O)N(H)-, (R )(H)N-,
10 1 10 1 10
(R )(alkyl)N-, (R )(H)NC(=A )N(H)-, and (R )(alkyl)NC(=A )N(H)-; wherein R is
selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or
1 10a
heterocyclyl; and A is selected from S and O; and R is selected from alkyl,
alkenyl, alkynyl perhaloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl.
The term “perhaloalkyl” used herein means an alkyl group as defined
hereinabove wherein all the hydrogen atoms of the said alkyl group are
FPAA2865PCT
substituted with halogen. The perhaloalkyl group is exemplified by
trifluoromethyl, pentafluoroethyl and the like.
The term “cycloalkyl" as used herein, means a monocyclic, bicyclic, or tricyclic
non-aromatic ring system containing from 3 to 14 carbon atoms, preferably
monocyclic cycloalkyl ring containing 3 to 6 carbon atoms. Examples of
monocyclic ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl, and cyclooctyl. Bicyclic ring systems are also exemplified by a
bridged monocyclic ring system in which two non-adjacent carbon atoms of the
monocyclic ring are linked by an alkylene bridge. Representative examples of
bicyclic ring systems include, but are not limited to, bicyclo[3.1.1]heptane,
bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane,
bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane, bicyclo[3.3.2]decane,
bicyclo[3.1.0]hexane, bicyclo[410]heptane, bicyclo[3.2.0]heptanes, octahydro-
1H-indene. Tricyclic ring systems are also exemplified by a bicyclic ring system
in which two non-adjacent carbon atoms of the bicyclic ring are linked by a
bond or an alkylene bridge. Representative examples of tricyclic-ring systems
include, but are not limited to, tricyclo[3.3.1.0 ]nonane and
tricyclo[3.3.1.1 ]decane (adamantane). The term cycloalkyl also include spiro
systems wherein one of the ring is annulated on a single carbon atom such ring
systems are exemplified by spiro[2.5]octane, spiro[4.5]decane,
spiro[bicyclo[4.1.0]heptane-2,1'-cyclopentane], hexahydro-2'H-
spiro[cyclopropane-1,1'-pentalene].
cycloalkyl as defined hereinabove may be substituted with one or more
substituents selected independently from the group comprising of oxo, halogen,
10a 10a 10 1
nitro, cyano, aryl, hereroaryl, alkyl, alkenyl, alkynyl, R C(=O)-, R SO -, R A -
10a 10a 10 10 10a
, R OC(=O)-, R C(=O)O-, (R )(H)NC(=O)-, (R )(alkyl)NC(=O)-, R C(=O)N(H)-,
10 10 1 10 1
(R )(H)N-, (R )(alkyl)N-, (R )(H)NC(=A )N(H)-, and (R )(alkyl)NC(=A )N(H)-;
wherein R is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl,
1 10a
cycloalkyl or heterocyclyl; and A is selected from S and O; and R is selected
from alkyl, alkenyl, alkynyl, perhaloalkyl, aryl, heteroaryl, cycloalkyl or
heterocyclyl
FPAA2865PCT
The term "aryl" refers to a monovalent monocyclic, bicyclic or tricyclic aromatic
hydrocarbon ring system. Examples of aryl groups include phenyl, naphthyl,
anthracenyl, fluorenyl, indenyl, azulenyl, and the like. Aryl group also include
partially saturated bicyclic and tricyclic aromatic hydrocarbons such as
tetrahydro-naphthalene. The said aryl group also includes aryl rings fused with
heteroaryl or heterocyclic rings such as 2,3-dihydro-benzo[1,4]dioxinyl; 2,3-
dihydro-benzo[1,4]dioxinyl; 2,3-dihydro-benzofuranyl; 2,3-dihydro-
benzofuranyl; 2,3-dihydro-benzofuranyl; 2,3-dihydro-benzofuranyl;
2,3-dihydro-1H-indolyl; 2,3-dihydro-1H-indolyl; 2,3-dihydro-1H-indol
yl; 2,3-dihydro-1H-indolyl; benzo[1,3]dioxolyl; benzo[1,3]dioxolyl;
1,2,3,4-tetrahydroquinolinyl; 1,2,3,4-tetrahydroisoquinolinyl; 2,3-
dihydrobenzothienyl, 2-oxoindolinyl.
Aryl as defined hereinabove may be substituted with one or more substituents
selected independently from the group comprising of halogen, nitro, cyano,
hydroxy, C to C alkyl, C to C alkenyl, C to C alkynyl, C to C cycloalkyl, 3-
1 6 2 6 2 6 3 6
to 6- membered heterocycle, C to C perhaloalkyl, alkyl-O-, alkenyl-O-, alkynyl-
O-, perhaloalkyl-O-, alkyl-N(alkyl)-, alkyl-N(H)-, H N-, alkyl-SO -, perhaloalkyl-
SO -, alkyl-C(=O)N(alkyl)-, alkyl-C(=O)N(H)-, alkyl-N(alkyl)C(=O)-, alkyl-
N(H)C(=O)-, H NC(=O)-, alkyl-N(alkyl)SO -, alkyl-N(H)SO -, H NSO -.
2 2 2 2 2
The term "heteroaryl" refers to a 5-14 membered monocyclic, bicyclic, or
tricyclic ring system having 1-4 ring heteroatoms selected from O, N, or S, and
the remainder ring atoms being carbon (with appropriate hydrogen atoms
unless otherwise indicated), wherein at least one ring in the ring system is
aromatic. Heteroaryl groups may be optionally substituted with one or more
substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a
heteroaryl group may be substituted by a substituent. Examples of heteroaryl
groups include pyridyl, 1-oxo-pyridyl, furanyl, thienyl, pyrrolyl, oxazolyl,
oxadiazolyl, imidazolyl, thiazolyl, isoxazolyl, quinolinyl, pyrazolyl, isothiazolyl,
pyridazinyl, pyrimidinyl, pyrazinyI, triazinyl. triazolyl, thiadiazolyl, isoquinolinyl,
benzoxazolyl, benzofuranyl, indolizinyl, imidazopyridyl, tetrazolyl,
benzimidazolyl, benzothiazolyl, benzothiadiazolyl, benzoxadiazolyl, indolyl,
azaindolyl, imidazopyridyl, quinazolinyl, purinyl, pyrrolo[2,3]pyrimidinyl,
pyrazolo[3,4]pyrimidinyl, and benzo(b)thienyl, 2,3-thiadiazolyl, 1H-pyrazolo[5,1-
FPAA2865PCT
c]-1,2,4-triazolyl, pyrrolo[3,4-d]-1,2,3-triazolyl, cyclopentatriazolyl, 3H-
pyrrolo[3,4-c] isoxazolyl and the like.
heteroaryl as defined hereinabove may be substituted with one or more
substituents selected independently from the group comprising of halogen,
nitro, cyano, hydroxy, C to C alkyl, C to C alkenyl, C to C alkynyl, C to C
1 6 2 6 2 6 3 6
cycloalkyl, 3- to 6- membered heterocycle, C to C perhaloalkyl, alkyl-O-,
alkenyl-O-, alkynyl-O-, perhaloalkyl-O-, alkyl-N(alkyl)-, alkyl-N(H)-, H N-, alkyl-
SO -, perhaloalkyl-SO -, alkyl-C(=O)N(alkyl)-, alkyl-C(=O)N(H)-, alkyl-
N(alkyl)C(=O)-, alkyl-N(H)C(=O)-, H NC(=O)-, alkyl-N(alkyl)SO -, and alkyl-
N(H)SO -, H NSO -.
2 2 2
The term "heterocycle" or "heterocyclic" as used herein, means a ‘cycloalkyl’
group wherein one or more of the carbon atoms replaced by –O-, -S-, -S(O )-, -
m m n m n
S(O)-, -N(R )-, -Si(R )R -, wherein, R and R are independently selected from
hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, and heterocyclyl.
The heterocycle may be connected to the parent molecular moiety through any
carbon atom or any nitrogen atom contained within the heterocycle.
Representative examples of monocyclic heterocycle include, but are not limited
to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-
dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl,
isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl.
oxadiazolidinyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl,
pyrazolinyl, pyrazolidinyl. pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl,
tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl,
thiomorpholinyl, 1.1-dioxidothiomorpholinyl (thiomorpholine sulfone).
thiopyranyl, and trithianyl. Representative examples of bicyclic heterocycle
include, but are not limited to 1,3-benzodioxolyl, 1,3-benzodithiolyl, 2,3-
dihydro-1,4-benzodioxinyl, 2,3-dihydrobenzofuranyl, 2,3-dihydro
benzothienyl, 2,3-dihydro-1 H-indolyl and 1,2,3,4-tetrahydroquinolinyl. The
term heterocycle also include bridged heterocyclic systems such as
azabicyclo[3.2.1]octane, azabicyclo[3.3.1]nonane and the like.
Heterocyclyl group may be substituted on ring carbons with one or more
substituents selected independently from the group comprising of oxo, halogen,
FPAA2865PCT
1 10a
nitro, cyano, aryl, hereroaryl, alkyl, alkenyl, alkynyl, R A -, R OC(=O)-,
10a 10 10 10a 10
R C(=O)O-, (R )(H)NC(=O)-, (R )(alkyl)NC(O)-, R C(=O)N(H)-, (R )(H)N-,
10 1 10 1 10
(R )(alkyl)N-, (R )(H)NC(=A )N(H)-, and (R )(alkyl)NC(=A )N(H)-; wherein R is
selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or
1 10a
heterocyclyl; and A is selected from S and O; and R is selected from alkyl,
alkenyl, alkynyl, perhaloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl.
Heterocyclyl group may further be substituted on ring nitrogen(s) with
substituents selected from the group comprising of aryl, hereroaryl, alkyl,
10a 10a 10a 10
alkenyl, alkynyl, R C(=O)-, R SO -, R OC(=O)-, (R )(H)NC(=O)-,
10
(R )(alkyl)NC(=O)-; wherein R is selected from hydrogen, alkyl, alkenyl,
alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and R is selected from
alkyl, alkenyl, alkynyl, perhaloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl.
The term ‘oxo’ means a divalent oxygen (=O) attached to the parent group. For
example oxo attached to carbon forms a carbonyl, oxo substituted on
cyclohexane forms a cyclohexanone, and the like.
The term ‘annulated’ means the ring system under consideration is either
annulated with another ring at a carbon atom of the cyclic system or across a
bond of the cyclic system as in the case of fused or spiro ring systems.
The term ‘bridged’ means the ring system under consideration contain an
alkylene bridge having 1 to 4 methylene units joining two non adjuscent ring
atoms.
A compound its stereoisomers, racemates, pharmaceutically acceptable salt
thereof as described hereinabove wherein the compound of general formula I is
selected from:
4-(2-(4-chlorophenyl)-3,5-dimethylpropionyl-1H-pyrrol
yl)benzenesulfonamide; and
4-(2-(4-chlorophenyl)ethylmethylpropionyl-1H-pyrrolyl)
benzenesulfonamide.
Prophetic compounds are listed below:
FPAA2865PCT
4-(2-(4-chlorophenyl)-3,5-dimethyl(pyrrolidinecarbonyl)-1H-pyrrolyl)
benzenesulfonamide.
4-(2-(4-chlorophenyl)((2S,6R)-2,6-dimethylmorpholinecarbonyl)-3,5-
dimethyl-1H-pyrrolyl)benzenesulfonamide.
4-(3-(3-azabicyclo[3.1.0]hexanecarbonyl)(4-chlorophenyl)-2,4-dimethyl-
1H-pyrrolyl)benzenesulfonamide.
4-(2-(4-chlorophenyl)-3,5-dimethyl(5-azaspiro[2.5]octanecarbonyl)-1H-
pyrrolyl)benzenesulfonamide.
4-(3-(8-oxaazabicyclo[3.2.1]octanecarbonyl)(4-chlorophenyl)-2,4-
dimethyl-1H-pyrrolyl)benzenesulfonamide.
According to another aspect of the present invention, the compounds of general
formula I where all the symbols are as defined earlier were prepared by methods
described below. However, the invention is not limited to these methods; the
compounds may also be prepared by using procedures described for
structurally related compounds in the literature.
Scheme 1 shows route of synthesis of compound of formula I from compound of
formula II.
FPAA2865PCT
Compound of formula II is subjected to Friedal–Crafts acylation with acid
chloride of formula III in the presence of an acid as described in the literature
EP 2168959 to obtain compound of formula IV. Friedal Craft reaction can be
carried out under different conditions well known in the art. Besides, a person
skilled in the art would appreciate various other possible methods to arrieve at
compound of formula IV, where R and R are same as described under
compound of formula I hereinabove.
The compounds of the formula IV where R and R are same as defined earlier in
compound of general formula I on halogenation gives compound of formula V.
Halogenation can be carried out according to the procedure generally used in
the synthetic organic chemistry using bromine, iodine, NCS, NBS, NIS, sufuryl
chloride, cupric chloride, cupric bromide or cupric iodide in an organic solvent
such as ethyl acetate, dichloromethane, methanol, THF, 1,4-dioxane, or the
like, or a suitable mixture thereof. Preferably halogenation is carried out using
bromine or cupric chloride in dichloromethane or methanol.
The compound of formula V where symbols R and R are same as defined for
compound IV, and X is halogen, when reacted with compound of formula VI,
where R is same as defined in compound of general formula I, in presence of
base such as potassium carbonate, sodium hydride preferably pulverized
sodium under room temperature to heated conditions in a solvent such as but
not limited to THF, acetonitrile, an aromatic hydrocarbon such as benzene and
toluene, preferably toluene provides diketo ester (compound of formula VII).
The compound of the formula VI can be prepared according to the procedure
given in literature such as Chem. Pharm. Bull. 1982, 30, 2590 and Journal of
Med. Chemistry, 1997, 40, 547.
1 3 4
The compound VII where symbols R , R , R are same as defined earlier is then
reacted with compound of formula VIIa under heating conditions in a solvent
such as acetic acid to obtain compound of the formula VIII.
Compound of formula VIIa is generally avalible commercially or the same can be
prepared using procedures provided in literature such as WO200429066 or
Chemistry, A European Journal 2011, 17(21), 5903 – 5907.
FPAA2865PCT
Hydrolysis of compound of the formula VIII gives compound of formula IX. The
hydrolysis may be carried out by standard procedure generally used in
synthetic organic chemistry or well known in the art using reagents such as
sodium hydroxide, potassium hydroxide and lithium hydroxide in solvents such
as alcohol, THF, water, or their mixture of suitable proportions. Preferably,
hydrolysis of compound of formula VIII is carried out using an aqueous solution
of sodium hydroxide and ethanol.
1 3 4 5
The compound of formula IX where R , R , R , R and ‘a’ are same as defined
earlier can be converted to its corresponding acid chloride using standard
procedures known in synthetic organic chemistry or preferably by reaction with
oxalyl chloride in dichloromethane along with DMF followed by reaction with
N,O-dimethylhydroxylamine hydrochloride in presence of triethylamine in
dichloromethane to provide compounds of formula X.
The compounds of the formula X can be reacted with Grignard reagents R MgX
where R is substituted- or unsubstituted- alkyl, and X is a halogen, to obtain
compound of formula I, where R is substituted- or unsubstituted- alkyl. The
reaction of compound of formula X with R MgX may be carried out according to
the procedure given in literature such as J. Med. Chem., 2009, 52, 3377.
Compound of formula IX is alternatively reacted with amines of formula
6 7 6 7 6 7 2
(R )(R )NH, (R )(OR )NH, where R and R are as defined under definition of R in
general formula I, except R C(=O)- and R SO -, to obtain compound of formula I,
2 6 7 6 7 6 7
where R is selected from (R )(R )N- and (R )(OR )N-, wherein R and R are as
2 9 9
defined under definition of R in general formula I, except R C(=O)- and R SO -.
The reaction was carried out according to the conditions known in converting
carboxylic acids to amides as known to one skilled in the art. The reaction may
be carried out in the presence of solvents, for example, DMF, THF, a
halogenated hydrocarbon such as chloroform and dichloromethane, an aromatic
hydrocarbon such as xylene, benzene, toluene, or mixtures thereof or the like,
in the presence of suitable base such as triethylamine, diisopropylethylamine,
pyridine or the like at a temperature between 0-50°C using reagents such as 1-
(3-dimethylaminopropyl)ethylcarbodimide hydrochloride (EDCI), 1,3-
dicyclohexylcarbodiimide (DCC), bis(2-oxooxazolidinyl)phosphinic chloride
FPAA2865PCT
(BOPCl), O-benzo triazolyl-N,N,N’,N’-tetramethyluronium tetrafluoroborate
(TBTU), O-(7-aza-benzo triazolyl)-N,N,N’,N’-tetramethyluronium
hexafluorophosphate (HATU), phosphonium based coupling agents such as 1-
benzo-triazolyloxytris-(pyrolidino) phosphonium hexafluorophosphate (PyBOP),
/DMAP, cyclophos, and auxillary reagents such as 1-hydroxy
azabenzotriazole (HOAT), hydroxybenzotriazole hydrate (HOBT) or the like.
2 6 7
The compounds of formula I, wherein R is selected as (R )(R )N- and
6 7a 6 7 9 9
(R )(OR )N-, wherein R and R are selected from R C(=O)- and R SO -, can be
prepared using the chemistry described in literature such as Tet. Lett. 2007, 48,
5181-5184 and Syn. Lett. 2005, 13, 2089-2091.
The term ‘room temperature’ denotes any temperature ranging between about
°C to about 40°C, except and otherwise it is specifically mentioned in the
specification.
The intermediates and the compounds of the present invention may obtained in
pure form in a manner known per se, for example, by distilling off the solvent in
vacuum and re-crystallizing the residue obtained from a suitable solvent, such
as pentane, diethyl ether, isopropyl ether, chloroform, dichloromethane, ethyl
acetate, acetone or their combinations or subjecting it to one of the purification
methods, such as column chromatography (e.g., flash chromatography) on a
suitable support material such as alumina or silica gel using eluent such as
dichloromethane, ethyl acetate, hexane, methanol, acetone and their
combinations. Preparative LC-MS method is also used for the purification of
molecules described herein.
Salts of compound of formula I can be obtained by dissolving the compound in a
suitable solvent, for example in a chlorinated hydrocarbon, such as methyl
chloride or chloroform or a low molecular weight aliphatic alcohol, for example,
ethanol or isopropanol, which was then treated with the desired acid or base as
described in Berge S.M. et al. “Pharmaceutical Salts, a review article in Journal
of Pharmaceutical sciences volume 66, page 1-19 (1977)” and in handbook of
pharmaceutical salts properties, selection, and use by P.H.Einrich Stahland
Camille G.wermuth, Wiley- VCH (2002). Lists of suitable salts can also be found
FPAA2865PCT
in Remington’s Pharmaceutical Sciences, 18th ed., Mack Publishing Company,
Easton, PA, 1990, p. 1445, and Journal of Pharmaceutical Science, 66, 2-19
(1977). For example, they can be a salt of an alkali metal (e.g., sodium or
potassium), alkaline earth metal (e.g., calcium), or ammonium of salt.
The compound of the invention or a composition thereof can potentially be
administered as a pharmaceutically acceptable acid-addition, base neutralized
or addition salt, formed by reaction with inorganic acids, such as hydrochloric
acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric
acid, and phosphoric acid, and organic acids such as formic acid, acetic acid,
propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid,
succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic
base, such as sodium hydroxide, potassium hydroxide. The conversion to a salt
is accomplished by treatment of the base compound with at least a
stoichiometric amount of an appropriate acid. Typically, the free base is
dissolved in an inert organic solvent such as diethyl ether, ethyl acetate,
chloroform, ethanol, methanol, and the like, and the acid is added in a similar
solvent. The mixture is maintained at a suitable temperature (e.g., between 0
°C and 50 °C). The resulting salt precipitates spontaneously or can be brought
out of solution with a less polar solvent.
The stereoisomers of the compounds of formula I of the present invention may
be prepared by stereospecific syntheses or resolution of the achiral compound
using an optically active amine, acid or complex forming agent, and separating
the diastereomeric salt/complex by fractional crystallization or by column
chromatography.
The term "prodrug" denotes a derivative of a compound, which derivative, when
administered to warm-blooded animals, e.g. humans, is converted into the
compound (drug). The enzymatic and/or chemical hydrolytic cleavage of the
compounds of the present invention occurs in such a manner that the proven
drug form (parent carboxylic acid drug) is released, and the moiety or moieties
split off remain nontoxic or are metabolized so that nontoxic metabolic products
are produced. For example, a carboxylic acid group can be esterified, e.g., with
FPAA2865PCT
a methyl group or ethyl group to yield an ester. When an ester is administered
to a subject, the ester is cleaved, enzymatically or non-enzymatically,
reductively, oxidatively, or hydrolytically, to reveal the anionic group. An
anionic group can be esterified with moieties (e.g., acyloxymethyl esters) which
are cleaved to reveal an intermediate compound which subsequently
decomposes to yield the active compound.
The prodrugs can be prepared in situ during the isolation and purification of the
compounds, or by separately reacting the purified compound with a suitable
derivatizing agent. For example, hydroxy groups can be converted into esters
via treatment with a carboxylic acid in the presence of a catalyst. Examples of
cleavable alcohol prodrug moieties include substituted or unsubstituted,
branched or unbranched lower alkyl ester moieties, e.g., ethyl esters, lower
alkenyl esters, di-lower alkylamino lower-alkyl esters, e.g., dimethylaminoethyl
ester, acylamino lower alkyl esters, acyloxy lower alkyl esters (e.g.,
pivaloyloxymethyl ester), aryl esters, e.g., phenyl ester, aryl-lower alkyl esters,
e.g., benzyl ester, optionally substituted, e.g., with methyl, halo, or methoxy
substituents aryl and aryl-lower alkyl esters, amides, lower-alkyl amides, di-
lwer alkyl amides, and hydroxy amides.
Modulation of the nicotinic cholinergic receptors, particularly α7 may provide
for efficacy in a range of cognitive states, right from pre-attention to attention
and subsequently working, reference and recognition memory. Accordingly, this
invention may find application in the treatment and prophylaxis of multitude of
disease conditions including, either one or combinations of, schizophrenia,
schizophreniform disorder, cognitive deficits in schizophrenia, brief psychotic
disorder, delusional disorder, schizoaffective disorder, shared psychotic
disorder, paranoid personality disorder, schizoid personality disorder,
schizotypal personality disorder, attention deficit disorder, attention deficit
hyperactivity disorder, depression, maniac depression, major depressive
disorder, posttraumatic stress disorder, generalized anxiety disorder, tourette’s
syndrome, cyclothymic disorder, dysthymic disorder, agoraphobia, panic
disorder (with or without agoraphobia), phobias (including social phobia) and
bipolar disorders (Thomsen MS et al., Curr. Pharm. Des., 2010, 16, 323-343;
FPAA2865PCT
Peng ZZ et al., Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2008, 25, 154-158;
Young JW et al., Eur. Neuropsychopharmacol., 2007, 17, 145-155; Martin LF et
al., Am. J. Med. Genet., B Neuropsychiatr. Genet., 2007, 144B, 611-614; Martin
LF et al., Psychopharmacology (Berl), 2004, 174, 54-64; Feher A et al., Dement.
Geriatr. Cogn. Disord., 2009, 28, 56-62; Wilens TE et al., Biochem. Pharmacol.,
2007, 74, 1212-1223; Verbois SL et al., Neuropharmacology, 2003, 44, 224-
233; Sanberg PR et al., Pharmacol. Ther., 1997, 74, 21-25). Cholinergic system,
particularly through α7 nAChR seems to have implications in traumatic brain
injury-induced psychosis. Chronic nicotine treatment has shown to attenuate
same. Thus, this invention may also find application in the treatment of deficits
in cholinergic α7 nAChR following traumatic brain injury (Bennouna M et al.,
Encephale, 2007, 33, 616-620; Verbois SL et al., Neuropharmacology, 2003, 44,
224-233).
Modulation of nicotinic ACh receptors, particularly the α7 subtype could also
help supplement the down-regulated cholinergic receptor expression and
transmission as in dementia(s), and also slowing disease progression by
reduction of α7-αβ complexation and internalization in AD and Down’s
1-42
syndrome (Nordberg A et al., Neurotox. Res., 2000, 2, 157-165; Haydar SN et
al., Bioorg. Med. Chem., 2009, 17, 5247-5258; Deutsch SI et al., Clin.
Neuropharmacol., 2003, 26, 277-283). Appropriately, this invention may find
application in the treatment and prophylaxis of multitude of disease conditions
including, either one or combinations of, dementia(s) due to Alzheimer’s disease,
dementia with Lewy bodies, Down’s syndrome, head trauma, Stroke,
hypoperfusion, Parkinson’s disease, Huntington’s disease, Prion diseases,
progressive supranuclear palsy, radiation therapy, brain tumors, normal-
pressure hydrocephalus, subdural hematoma, human immunodeficiency virus
(HIV) infection, vitamin deficiency, hypothyroidism, drugs, alcohol, lead,
mercury, aluminium, heavy metals, syphilis, Lyme disease, viral encephalitis,
fungal infection and cryptococcosis (Zhao X et al., Ann. N. Y. Acad. Sci., 2001,
939, 179-186; Perry E et al., Eur. J. Pharmacol., 2000, 393, 215-222;
Harrington CR et al., Dementia, 1994, 5, 215-228; Wang J et al., J. Neurosci.
Res., 2010, 88, 807-815; Duris K et al., Stroke 2011, 42(12), 3530-6). Thus, this
invention may also find application in the prophylaxis and preventive measures
FPAA2865PCT
immediately after early-stage identification of neurodegenerative disease like
Alzheimer’s disease and Parkinson’s disease.
Modulation of nicotinic ACh receptors particularly α4β2, α3β4 and α7 may have
implications in the development of therapies for nicotine, cannabis addiction
and relapse prevention. Accordingly, this invention may find application in the
prophylaxis or therapy of nicotine addiction, cannabis addiction, and relapse
prevention of nicotine or cannabis addiction. Additionally, this invention may
also provide for an alternative therapy for non-responding addiction patients,
patients having intolerable side-effects with de-addiction therapies or those
requiring long-term maintenance therapies. (Kuzmin A et al.,
Psychopharmacology (Berl), 2009, 203, 99-108; Weiss RB et al., PLoS Genet.,
2008, 4, e1000125; Solinas M et al., J. Neurosci., 2007, 27, 5615-5620; Ebbert
JO et al., Patient. Prefer. Adherence, 2010, 4, 355-362)
This invention may also find application in the treatment and prophylaxis of
multitude of pain conditions including, either one or combinations of, pain
arising from, peripheral nervous system (PNS), post-diabetic neuralgia (PDN),
post-herpetic neuralgia (PHN), multiple sclerosis, Parkinson’s disease, low-back
pain, fibromyalgia, post-operative pain, acute pain, chronic pain,
mononeuropathy, primary lateral sclerosis, pseudobulbar palsy, progressive
muscular palsy, progressive bulbar palsy, postpolio syndrome, diabetes induced
polyneuropathy, acute demyelinating polyneuropathy (Guillain-Barre
syndrome), acute spinal muscular atrophy (Werdnig-Hoffman disease) and
secondary neurodegeneration (Donnelly-Roberts DL et al., J. Pharmacol. Exp.
Ther., 1998, 285, 777-786; Rowley TJ et al., Br. J. Anaesth., 2010, 105, 201-
207; Bruchfeld A et al., J. Intern. Med., 2010, 268, 94-101).
This invention may find application in the treatment and prophylaxis of plethora
of inflammation and pain related states involving TNF-α and thus providing
symptomatic relief in either any one or combination of, rheumatoid arthritis,
bone resorption diseases, atherosclerosis, inflammatory bowel disease, Crohn’s
disease, inflammation, cancer pain, muscle degeneration, osteoarthritis,
osteoporosis, ulcerative colitis, rhinitis, pancreatitis, spondylitis, acute
FPAA2865PCT
respiratory distress syndrome (ARDS), joint inflammation, anaphylaxis,
ischemia reperfusion injury, multiple sclerosis, cerebral malaria, septic shock,
tissue rejection of graft, brain trauma, toxic shock syndrome, herpes virus
infection (HSV-1 & HSV-2), herpes zoster infection, sepsis, fever, myalgias,
asthma, uveititis, contact dermatitis, obesity-related disease and endotoxemia
(Giebelen IA T et al., Shock, 2007, 27, 443-447; Pena G et al., Eur. J. Immunol.,
2010, 40, 2580-2589).
Thus the present invention further provides a pharmaceutical composition,
containing the compounds of the general formula (I) as defined above, its
tautomeric forms, its stereoisomers, its pharmaceutically acceptable salts, its
polymorphs, its solvates, its optical isomers, its clathrates and its co-crystals in
combination with the usual pharmaceutically acceptable carriers, diluents and
the like.
The pharmaceutically acceptable carrier (or excipient) is preferably one that is
chemically inert to the compound of the invention and one that has no
detrimental side effects or toxicity under the conditions of use. Such
pharmaceutically acceptable carriers preferably include saline (e.g., 0.9%
saline), Cremophor EL (which is a derivative of castor oil and ethylene oxide
available from Sigma Chemical Co., St. Louis, MO) (e.g., 5% Cremophor EL/5%
ethanol/90% saline, 10% Cremophor EL/90% saline, or 50% Cremophor
EL/50% ethanol), propylene glycol (e.g., 40% propylene glycol/10%
ethanol/50% water), polyethylene glycol (e.g., 40% PEG 400/60% saline), and
alcohol (e.g., 40% ethanol/60% water). A preferred pharmaceutical carrier is
polyethylene glycol, such as PEG 400, and particularly a composition
comprising 40% PEG 400 and 60% water or saline. The choice of carrier will be
determined in part by the particular compound chosen, as well as by the
particular method used to administer the composition. Accordingly, there is a
wide variety of suitable formulations of the pharmaceutical composition of the
present invention.
FPAA2865PCT
The following formulations for oral, aerosol, parenteral, subcutaneous,
intravenous, intraarterial, intramuscular, interperitoneal, rectal, and vaginal
administration are merely exemplary and are in no way limiting.
The pharmaceutical compositions can be administered parenterally, e.g.,
intravenously, intraarterially, subcutaneously, intradermally, intrathecally, or
intramuscularly. Thus, the invention provides compositions for parenteral
administration that comprise a solution of the compound of the invention
dissolved or suspended in an acceptable carrier suitable for parenteral
administration, including aqueous and non-aqueous, isotonic sterile injection
solutions.
Overall, the requirements for effective pharmaceutical carriers for parenteral
compositions are well known to those of ordinary skill in the art. See
Pharmaceutics and Pharmacy Practice, J.B. Lippincott Company, Philadelphia,
PA, Banker and Chalmers, eds., pages 238-250 (1982), and ASHP Handbook on
Injectable Drugs, Toissel, 4th ed., pages 622-630 (1986). Such compositions
include solutions containing anti-oxidants, buffers, bacteriostats, and solutes
that render the formulation isotonic with the blood of the intended recipient,
and aqueous and non-aqueous sterile suspensions that can include suspending
agents, solubilizers, thickening agents, stabilizers, and preservatives. The
compound can be administered in a physiologically acceptable diluent in a
pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including
water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as
ethanol, isopropanol (for example in topical applications), or hexadecyl alcohol,
glycols, such as propylene glycol or polyethylene glycol, dimethylsulfoxide,
glycerol ketals, such as 2,2-dimethyl-1,3-dioxolanemethanol, ethers, such as
poly(ethyleneglycol) 400, an oil, a fatty acid, a fatty acid ester or glyceride, or an
acetylated fatty acid glyceride with or without the addition of a pharmaceutically
acceptable surfactant, such as a soap or a detergent, suspending agent, such as
pectin, carbomers, methylcellulose, hydroxypropylmethylcellulose, or
carboxymethylcellulose, or emulsifying agents and other pharmaceutical
adjuvants.
FPAA2865PCT
Oils useful in parenteral formulations include petroleum, animal, vegetable, and
synthetic oils. Specific examples of oils useful in such formulations include
peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral oil.
Suitable fatty acids for use in parenteral formulations include oleic acid, stearic
acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of
suitable fatty acid esters.
Suitable soaps for use in parenteral formulations include fatty alkali metal,
ammonium, and triethanolamine salts, and suitable detergents include (a)
cationic detergents such as, for example, dimethyl dialkyl ammonium halides,
and alkyl pyridinium halides, (b) anionic detergents such as, for example, alkyl,
aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and
sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine
oxides, fatty acid alkanolamides, and polyoxyethylene polypropylene
copolymers, (d) amphoteric detergents such as, for example, alkyl-β-
aminopropionates, and 2-alkyl-imidazoline quaternary ammonium salts, and (e)
mixtures thereof.
The parenteral formulations typically will contain from about 0.5% or less to
about 25% or more by weight of a compound of the invention in solution.
Preservatives and buffers can be used. In order to minimize or eliminate
irritation at the site of injection, such compositions can contain one or more
nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about
12 to about 17. The quantity of surfactant in such formulations will typically
range from about 5% to about 15% by weight. Suitable surfactants include
polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the
high molecular weight adducts of ethylene oxide with a hydrophobic base,
formed by the condensation of propylene oxide with propylene glycol. The
parenteral formulations can be presented in unit-dose or multi-dose sealed
containers, such as ampoules and vials, and can be stored in a freeze-dried
(lyophilized) condition requiring only the addition of the sterile liquid excipient,
for example, water, for injections, immediately prior to use. Extemporaneous
injection solutions and suspensions can be prepared from sterile powders,
granules, and tablets.
FPAA2865PCT
Topical formulations, including those that are useful for transdermal drug
release, are well known to those of skill in the art and are suitable in the context
of the present invention for application to skin.
Formulations suitable for oral administration can consist of (a) liquid solutions,
such as an effective amount of a compound of the invention dissolved in
diluents, such as water, saline, or orange juice; (b) capsules, sachets, tablets,
lozenges, and troches, each containing a pre-determined amount of the
compound of the invention, as solids or granules; (c) powders; (d) suspensions
in an appropriate liquid; and (e) suitable emulsions. Liquid formulations can
include diluents, such as water and alcohols, for example, ethanol, benzyl
alcohol, and the polyethylene alcohols, either with or without the addition of a
pharmaceutically acceptable surfactant, suspending agent, or emulsifying
agent. Capsule forms can be of the ordinary hard- or soft-shelled gelatin type
containing, for example, surfactants, lubricants, and inert fillers, such as
lactose, sucrose, calcium phosphate, and cornstarch. Tablet forms can include
one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic
acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon
dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate,
zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering
agents, disintegrating agents, moistening agents, preservatives, flavoring agents,
and pharmacologically compatible excipients. Lozenge forms can comprise the
compound ingredient in a flavor, usually sucrose and acacia or tragacanth, as
well as pastilles comprising a compound of the invention in an inert base, such
as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like
containing, in addition to the compound of the invention, such excipients as are
known in the art.
An compound of the present invention, alone or in combination with other
suitable components, can be made into aerosol formulations to be administered
via inhalation. A compound or epimer of the invention is preferably supplied in
finely divided form along with a surfactant and propellant. Typical percentages
of the compounds of the invention can be about 0.01% to about 20% by weight,
FPAA2865PCT
preferably about 1% to about 10% by weight. The surfactant must, of course,
be nontoxic, and preferably soluble in the propellant. Representative of such
surfactants are the esters or partial esters of fatty acids containing from 6 to 22
carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic,
linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its
cyclic anhydride. Mixed esters, such as mixed or natural glycerides can be
employed. The surfactant can constitute from about 0.1% to about 20% by
weight of the composition, preferably from about 0.25% to about 5%. The
balance of the composition is ordinarily propellant. A carrier can also be
included as desired, e.g., lecithin, for intranasal delivery. These aerosol
formulations can be placed into acceptable pressurized propellants, such as
dichlorodifluoromethane, propane, nitrogen, and the like. They also can be
formulated as pharmaceuticals for non-pressured preparations, such as in a
nebulizer or an atomizer. Such spray formulations can be used to spray
mucosa.
Additionally, the compound of the invention can be made into suppositories by
mixing with a variety of bases, such as emulsifying bases or water-soluble
bases. Formulations suitable for vaginal administration can be presented as
pessaries, tampons, creams, gels, pastes, foams, or spray formulas containing,
in addition to the compound ingredient, such carriers as are known in the art to
be appropriate.
The concentration of the compound in the pharmaceutical formulations can
vary, e.g., from less than about 1% to about 10%, to as much as 20% to 50% or
more by weight, and can be selected primarily by fluid volumes, and viscosities,
in accordance with the particular mode of administration selected.
For example, a typical pharmaceutical composition for intravenous infusion
could be made up to contain 250 ml of sterile Ringer’s solution, and 100 mg of
at least one compound of the invention. Actual methods for preparing
parenterally administrable compounds of the invention will be known or
apparent to those skilled in the art and are described in more detail in, for
FPAA2865PCT
example, Remington’s Pharmaceutical Science (17 ed., Mack Publishing
Company, Easton, PA, 1985).
It will be appreciated by one of ordinary skill in the art that, in addition to the
aforedescribed pharmaceutical compositions, the compound of the invention
can be formulated as inclusion complexes, such as cyclodextrin inclusion
complexes, or liposomes. Liposomes can serve to target a compound of the
invention to a particular tissue, such as lymphoid tissue or cancerous hepatic
cells. Liposomes can also be used to increase the half-life of a compound of the
invention. Many methods are available for preparing liposomes, as described in,
for example, Szoka et al., Ann. Rev. Biophys. Bioeng., 9, 467 (1980) and U.S.
Patents 4,235,871, 4,501,728, 4,837,028, and 5,019,369.
The compounds or pharmaceutical compositions are useful, in an embodiment,
for the treatment and/or prophylaxis of diseases or disorder or condition such
as Alzheimer's disease (AD), mild cognitive impairment (MCI), senile dementia,
vascular dementia, dementia of Parkinson’s disease, attention deficit disorder,
attention deficit hyperactivity disorder (ADHD), dementia associated with Lewy
bodies, AIDS dementia complex (ADC), Pick's disease, dementia associated with
Down's syndrome, Huntington's disease, cognitive deficits associated with
traumatic brain injury (TBI), cognitive decline associated with stroke, poststroke
neuroprotection, cognitive and sensorimotor gating deficits associated with
schizophrenia, cognitive deficits associated with bipolar disorder, cognitive
impairments associated with depression, acute pain, post-surgical or post-
operative pain, chronic pain, inflammation, inflammatory pain, neuropathic
pain, smoking cessation, need for new blood vessel growth associated with
wound healing, need for new blood vessel growth associated with
vascularization of skin grafts, and lack of circulation, arthritis, rheumatoid
arthritis, psoriasis, Crohn's disease, ulcerative colitis, pouchitis, inflammatory
bowel disease, celiac disease, periodontitis, sarcoidosis, pancreatitis, organ
transplant rejection, acute immune disease associated with organ
transplantation, chronic immune disease associated with organ transplantation,
septic shock, toxic shock syndrome, sepsis syndrome, depression, and
rheumatoid spondylitis.
FPAA2865PCT
In another embodiment, the pharmaceutical compositions are useful for the
treatment and/or prophylaxis of diseases or disorder or condition classified or
diagnosed as major or minor neurocognitive disorders, or disorders arising due
to neurodegeneration.
Also described herein is a method of administering a compound of formula I, as
defined hereinabove in combination with or as adjunct to medications used in
the treatment of attention deficit hyperactivity disorders, schizophrenia, and
other cognitive disorders such as Alzheimer's disease, Parkinson’s dementia,
vascular dementia or dementia associated with Lewy bodies, traumatic brain
injury.
Also described herein is a method of administering a compound of formula I, as
defined hereinabove in combination with or as an adjunct to
acetylcholinesterase inhibitors, disease modifying drugs or biologics for
neurodegenerative disorders, dopaminergic drugs, antidepressants, typical or
an atypical antipsychotic.
Accordingly, compound of formula I is useful for preventing or treating a
disorder mediated by nicotinic acetylcholine receptors. Such compounds can be
administered to a subject having such a disorder or susceptible to such
disorders in a therapeutically effective amount. The compounds are particularly
useful for a method of treating a mammal having a condition where modulation
of nicotinic acetylcholine receptor activity is of therapeutic benefit, wherein the
method is accomplished by administering a therapeutically effective amount of a
compound of formula I to a subject having, or susceptible to, such a disorder.
The present invention also provides a pharmaceutical composition, containing
the compounds of the general formula (I) as defined above, its tautomeric forms,
its stereoisomers, its pharmaceutically acceptable salts, its polymorphs, its
solvates, its optical isomers, its clathrates and its co-crystals in combination
with the usual pharmaceutically employed carriers, diluents and the like, and
for use in any of the methods described herein.
FPAA2865PCT
The compounds of the invention can be administered in a dose sufficient to
treat the disease, condition or disorder. Such doses are known in the art (see,
for example, the Physicians’ Desk Reference (2004)). The compounds can be
administered using techniques such as those described in, for example,
Wasserman et al., Cancer, 36, pp. 1258-1268 (1975) and Physicians’ Desk
Reference, 58th ed., Thomson PDR (2004).
Suitable doses and dosage regimens can be determined by conventional range-
finding techniques known to those of ordinary skill in the art. Generally,
treatment is initiated with smaller dosages that are less than the optimum dose
of the compound of the present invention. Thereafter, the dosage is increased
by small increments until the optimum effect under the circumstances is
reached. The present method can involve the administration of about 0.1 μg to
about 50 mg of at least one compound of the invention per kg body weight of the
individual. For a 70 kg patient, dosages of from about 10 μg to about 200 mg of
the compound of the invention would be more commonly used, depending on a
patient’s physiological response.
By way of example and not intending to limit the invention, the dose of the
pharmaceutically active agent(s) described herein for methods of treating or
preventing a disease or condition as described above can be about 0.001 to
about 1 mg/kg body weight of the subject per day, for example, about 0.001 mg,
0.002 mg, 0.005 mg, 0.010 mg, 0.015 mg, 0.020 mg, 0.025 mg, 0.050 mg,
0.075 mg, 0.1 mg, 0.15 mg, 0.2 mg, 0.25 mg, 0.5 mg, 0.75 mg, or 1 mg/kg body
weight per day. The dose of the pharmaceutically active agent(s) described
herein for the described methods can be about 1 to about 1000 mg/kg body
weight of the subject being treated per day, for example, about 1 mg, 2 mg, 5
mg, 10 mg, 15 mg, 0.020 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg,
250 mg, 500 mg, 750 mg, or 1000 mg/kg body weight per day.
FPAA2865PCT
Also described herein are methods of treating, preventing, ameliorating, and/or
inhibiting a condition modulated by the nicotinic acetylchoine receptor
comprising administering a compound of formula (I) or a salt thereof.
The terms “treat,” “prevent,” “ameliorate,” and “inhibit,” as well as words
stemming therefrom, as used herein, do not necessarily imply 100% or complete
treatment, prevention, amelioration, or inhibition. Rather, there are varying
degrees of treatment, prevention, amelioration, and inhibition of which one of
ordinary skill in the art recognizes as having a potential benefit or therapeutic
effect. In this respect, the inventive methods can provide any amount of any
level of treatment, prevention, amelioration, or inhibition of the disorder in a
mammal. For example, a disorder, including symptoms or conditions thereof,
may be reduced by, for example, 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%,
%, or 10%. Furthermore, the treatment, prevention, amelioration, or
inhibition provided by the inventive method can include treatment, prevention,
amelioration, or inhibition of one or more conditions or symptoms of the
disorder, e.g., cancer. Also, for purposes herein, “treatment,” “prevention,”
“amelioration,” or “inhibition” can encompass delaying the onset of the disorder,
or a symptom or condition thereof.
In accordance with the invention, the term subject includes an “animal” which
in turn includes a mammal such as, without limitation, the order Rodentia,
such as mice, and the order Lagomorpha, such as rabbits. It is preferred that
the mammals are from the order Carnivora, including Felines (cats) and
Canines (dogs). It is more preferred that the mammals are from the order
Artiodactyla, including Bovines (cows) and Swine (pigs) or of the order
Perssodactyla, including Equines (horses). It is most preferred that the
mammals are of the order Primates, Ceboids, or Simoids (monkeys) or of the
order Anthropoids (humans and apes). An especially preferred mammal is the
human.
Following are the abbreviations used and meaning thereof in the specification:
ACh: Acetylcholine.
FPAA2865PCT
AD: Alzheimer ’s disease.
ADC: AIDS dementia complex.
ADHD: attention deficit hyperactivity disorder.
AIDS: Acquired immunodeficiency syndrome.
ARDS: acute respiratory distress syndrome.
DCC: 1,3-dicyclohexylcarbodiimide.
DCE: dichloroethane.
DCM: dichloromethane.
DIPEA: diisopropyl ethyl amine
DLB: dementia with Lewy bodies.
DMF: N,N-dimethylformamide.
EDCI: 1-(3-dimethylaminopropyl)ethylcarbodimide hydrochloride.
FLIPR: Fluorometric Imaging Plate Reader.
HATU: 2-(1HAzabenzotriazolyl)-1,1,3,3-tetramethyl uronium
hexafluorophosphate.
HBSS: Hank's balanced salt solution.
HEPES: 4-(2-hydroxyethyl)piperazineethanesulfonic acid.
HMGB: high mobility group box.
HOAT: 1-hydroxyazabenzotriazole.
HOBT: hydroxybenzotriazole hydrate.
HPLC: High Performance liquid chromatography.
IL: interleukins.
LDT: laterodorsal tegmental nucleus.
LGIC: ligand-gated ion channels.
MCI: mild cognitive impairment.
NBS: N-bromosuccinimide.
NCS: N-chlorosuccinimide.
NIS: N-iodosuccinamide
NNRs: Neural nicotinic ACh receptors.
PAM: positive allosteric modulation.
PD: Parkinson’s disease.
PDN: post-diabetic neuralgia.
PHN: post-herpetic neuralgia.
PMBO: p-methoxy benzyloxy.
FPAA2865PCT
PNS: peripheral nervous system.
TBI: traumatic brain injury.
THF: Tetrahydrofuran.
TLC: Thin layer chromatography.
TMS: tetramethylsilane.
TNF-α: tumor necrosis factor alpha.
VTA: ventral tegmental area.
α7 nAChR: nicotinic acetylcholine receptor α7 subunit.
The following examples are provided to further illustrate the present invention
and therefore should not be construed in any way to limit the scope of the
present invention. All HNMR spectra were determined in the solvents indicated
and chemical shifts are reported in δ units downfield from the internal standard
tetramethylsilane (TMS) and interproton coupling constants are reported in
Hertz (Hz).
Example 1: Synthesis of 4-(2-(4-chlorophenyl)-3,5-dimethylpropionyl-1H-
pyrrolyl) benzenesulfonamide (Compound 1)
Step 1: Ethyl 5-(4-chlorophenyl)-2,4-dimethyl(4-sulfamoylphenyl)-1H-
pyrrolecarboxylate
A mixture of ethyl [2-acetyl(4-chlorophenyl)methyloxo]butyrate
(prepared according to the procedure given in Med.Chem. Res.(1994),5, 54-62,
1.6g, 5.39 mmol) and 4-aminobenzenesulfonamide (0.928g, 5.39 mmol) in acetic
acid (40 ml) was heated at 95 C for 17 hr under stirring. The completion of
FPAA2865PCT
reaction was monitored by TLC. Reaction mixture was concentrated at reduced
pressure. Dichloromethane (100 ml) was added to the residue, washed with
water (1x 25 ml). Organic layer was dried over anhydrous Na SO . The solvent
was evaporated under reduced pressure to obtain a crude product; which was
purified by column chromatography over silica gel (100-200 mesh) using 1%
methanol in dichloromethane as an eluent to yield the title compound (1.65 g,
71%)
MS: m/z 433 (M+1)
HNMR (CDCl , 400 MHz): δ 7.90 (d, J=8.4 Hz, 2H), 7.16-7.25 (m, 4H), 6.92 (d,
J=8.4 Hz, 2H), 4.93 (bs, exchanged with D O 2H), 4.33 (q, J=7.2Hz, 2H), 2.37 (s,
3H), 2.23 (s, 3H), 1.38 (t, J= 7.2 Hz, 3H).
Step 2: 5-(4-Chlorophenyl)-2,4-dimethyl(4-sulfamoylphenyl)-1H-pyrrole
carboxylic acid
SO NH
Ethyl 5-(4-chlorophenyl)-2,4-dimethyl(4-sulfamoylphenyl)-1H-pyrrole
carboxylate
(Step 1, 1.6g, 3.69 mmol) was suspended in ethanol (50 ml) and treated with
aqueous solution of NaOH (2.22g in 20 ml. water) at room temperatue. The
reaction mixture was refluxed for 3 hr. The completion of reaction was
monitored by TLC. Reaction mixture was concentrated at reduced pressure.
Residue was taken in mixture of solvents ethyl acetate and dichloromethane in
1:1 ratio (75 ml.). Organinc layer was decanted and solid so obtained was taken
in water (25 ml) and neutralized with 5N HCl upto pH7, Aqueous layer was
extracted with ethyl acetate (2 x 50 ml). Combined organic layer was dried over
FPAA2865PCT
anhydrous Na SO . The solvent was evaporated under reduced pressure to
obtain a product. (1.47g, 98%)
MS: m/z 405 (M+1)
HNMR (DMSO-D6, 400 MHz): δ 12.03 (bs, exchanges with D O, 1H), 7.80 (d,
J=8.4 Hz, 2H), 7.41 (bs, exchanged with D O 2H), 7.38 (d, J=8.4 Hz, 2H), 7.31
(d, J=8.4 Hz, 2H), 7.06 (d, J=8.4 Hz, 2H), 2.28 (s, 3H), 2.15 (s, 3H).
Step 3: 5-(4-Chlorophenyl)(4-(N-
((dimethylamino)methylene)sulfamoyl)phenyl)- N-methoxy-N,2,4-trimethyl-1H-
pyrrolecarboxamide
Oxalyl chloride (0.908g, 0.60 ml, 7.16 mmol) was added dropwise at 0 C to a
solution of 5-(4-Chlorophenyl)-2,4-dimethyl(4-sulfamoylphenyl)-1H-pyrrole-
3-carboxylic acid (step 2, 1.45g, 3.58 mmol) in dichloromethane (50 ml)/ DMF
(0.544g, 0.50 ml,7.16 m mol). Mixture was allowed to come at room temperature
and stirred for 1 hr. under nitrogen atmosphere. The completion of reaction was
monitored by TLC. The mixture was concentrated under reduced pressure
under nitrogen atmosphere. To this residue was added N,O-
dimethylhydroxylamine hydrochloride (0.690g, 7.16 mmol) in dry
dichloromethane (50 ml) at 0 C followed by the addition of triethylamine (1.44g,
2.0ml, 14.32 mmol,) under stirring. The reaction mixture was stirred at room
temperature for 2 hr. The completion of reaction was monitored by TLC. The
solvent was removed under reduced pressure. The residue so obtained was
taken in dichloromethane (50 ml), washed with water (2x 25 ml.) and organic
layers separated were dried over anhydrous sodium sulphate, filtered and
concentrated at reduced pressure to get a crude product. This crude product
FPAA2865PCT
was purified by column chromatography over silica gel (100-200 mesh) using
0.8% methanol in dichloromethane as an eluent to yield the title compound
(0.763g, 42%).
MS: m/z 503 (M+1)
HNMR (CDCl , 400 MHz): δ 8.13 (s, 1H), 7..82 (d, J=8.4 Hz, 2H), 7.15 (d, J=8.4
Hz, 2H), 7.10 (d, J=8.4 Hz, 2H), 6.91 (d, J=8.4 Hz, 2H), 3.67 (s, 3H), 3.37 (s, 3H),
3.15 (s, 3H), 3.04 (s, 3H), 2.13 (s, 3H), 2.10 (s, 3H).
Step 4: 4-(2-(4-chlorophenyl)-3,5-dimethylpropionyl-1H-pyrrolyl)
benzenesulfonamide
SO NH
To a stirred solution of 5-(4-Chlorophenyl)(4-(N-((dimethylamino) methylene)
sulfamoyl) phenyl)- N-methoxy-N,2,4-trimethyl-1H-pyrrolecarboxamide (step
3, 0.750g, 1.49 mmol) in anhydrous THF (50 ml) at 0 C, ethyl magnesium
bromide (Grignard reagent, 0.994g, 7.4 ml, 7.46 mmol) was added dropwise
and reaction mixture was heated to reflux for 1 h. The completion of reaction
was monitored by TLC. After cooling, reaction mixture was quenched by
addition of solution of saturated ammonium chloride (10 ml) and extracted with
ethyl acetate (1 x50 ml). Combined organic layer was dried over anhydrous
Na SO . The solvent was evaporated under reduced pressure to obtain a crude
product; which was purified by column chromatography over silica gel (100-200
mesh) using 0.4% methanol in dichloromethane as an eluent to yield the title
compound which was finally purified by preparative HPLC (0.062g, 10 %)
MS: m/z 417(M+1)
FPAA2865PCT
HNMR (CDCl , 400 MHz): δ 7.88 (d, J=8.8Hz, 2H), 7.16-7.19 (m, 4H), 6.91 (d,
J=8.4Hz, 2H), 4.92 (bs, exchanged with D O 2H), 2.84 (q, J=7.2Hz, 2H), 2.34 (s,
3H), 2.24 (s, 3H), 1.21 (t, J= 7.2 Hz, 3H).
Example 2: Preparation of 4-(2-(4-chlorophenyl)ethylmethyl
propionyl-1H-pyrrolyl)benzenesulfonamide (Compound 2).
Compound 2 was prepared using appropriate reagents and by following a
procedure analogous to the one provided under example 1.
4-(2-(4-chlorophenyl)ethylmethylpropionyl-1H-pyrrolyl)
benzenesulfonamide (Compound 2)
MS: m/z 431 (M+1),
HNMR (DMSO-D6, 400 MHz): δ 7.78 (d, J=8.4Hz, 2H), 7.46 (bs-exchanged with
D O, 2H), 7.39 (d, J=8.4Hz, 2H), 7.31 (d, J=8.4Hz, 2H), 7.10 (d, J=8.4Hz, 2H),
2.82 (q, J=7.2Hz, 2H), 2.53 (q, J=7.2Hz, 2H), 2.26 (s, 3H), 1.10 (t, J=7.2Hz, 3H),
1.02 (t, J=7.2Hz, 3H).
Example 3: Pharmacological screening
Compounds were tested in a cell-based real-time kinetic assay in human IMR-
32 cells with native expression of α7nAChR. The increase in intracellular Ca
levels was measured in a Fluorometric Imaging Plate Reader (FLIPR). Test
compound and agonist solutions were made in assay buffer (HBSS, pH 7.4, 20
mM HEPES, and 10 mM CaCl ). Briefly, cells were plated into Poly-D-Lysine
coated back-walled clear-bottom 96-well microplates at a density of 80,000 to
100,000 cells/well and incubated at 37°C/5% CO2 for 40-48 h prior to the
experiment. For evaluation of compound mediated potentiation of agonist
response, growth media was removed from the wells and 200 µl of FLIPR
FPAA2865PCT
calcium 4 dye (Molecular Devices), reconstituted in assay buffer, and was added
to the wells. After dye loading, microplates were incubated for 30 min at 37°C
and 30 min at room temperature and then directly transferred to the FLIPR.
Baseline fluorescence was monitored for the first 10 to 30 s followed by the
addition of 25 µl of test compound solution and subsequent monitoring of
fluorescence changes for up to 10 min. This was followed by addition of 25 µl of
agonist solution (PNU-282987, 10 µM) and measurement of fluorescence for 4
min. (Faghih R. et al. 2009, J. Med. Chem., 52, 3377 – 84.)
The compound induced fold increase in agonist response (fold PAM activity) was
computed by dividing the maximum effect (Max-Min fluorescence) obtained with
test compound in presence of agonist with the agonist-alone effect. EC of the
compound was calculated using GraphPad Prism software version 5.0, by
plotting compound concentrations against fold PAM activity.
Fold activity at 1µM concentration: Compounds of invention showed increase in
the activity by between about 20 to about 25 folds.
FPAA2865PCT
Claims (17)
1. A compound of formula I, its tautomeric forms, its stereoisomers, its sulfoxides, its N-oxides, its pharmaceutically acceptable salts, its 5 polymorphs, its solvates, its optical isomers, its clathrates or its co- crystals, [ ] SO NH (I) 2 2 wherein, R is selected from the group consisting of hydrogen, halogen, 10 substituted- or unsubstituted- alkyl, substituted- or unsubstituted- alkenyl, substituted- or unsubstituted- alkynyl, perhaloalkyl, and substituted- or unsubstituted- cycloalkyl; R is selected from the group consisting of substituted- or unsubstituted- 6 7 6 7a 6a alkyl, (R )(R )N-, (R )N(OR )-, and R O-; 15 R is selected from the group consisting of substituted- or unsubstituted- alkyl, substituted- or unsubstituted- alkenyl, substituted- or unsubstituted- alkynyl, substituted- or unsubstituted- cycloalkyl; R is selected from the group consisting of substituted- or unsubstituted- aryl, substituted- or unsubstituted- heteroaryl; 5 5 5 20 [R ] is ‘a’ times repetition of ‘R ’ groups, each R is independently selected from the group consisting of halo, substituted- or unsubstituted- alkyl, R O-; ‘a’ is an integer selected from 0, 1, and 2; FPAA2865PCT wherein, R and R are independently selected from hydrogen, substituted- or unsubstituted- alkyl, R C(=O)-, R SO -; such that when 2 6 7 6 7 R is (R )(R )N-, R and R together with the nitrogen atom to which they are attached may form a 3 to 10 member substituted- or unsubstituted- 5 heterocycle containing one to three hetero atoms/groups selected from the group consisting of S, N, O the said heterocycle may be saturated or unsaturated, monocyclic or bicyclic or spiro, or the said heterocycle may contain an alkylene bridge; R is selected from hydrogen and substituted- or unsubstituted- alkyl; 10 R is selected as substituted- or unsubstituted- alkyl; wherein R is selected from hydrogen, substituted- or unsubstituted- alkyl, and perhaloalkyl; wherein, R is independently selected from the group consisting of hydrogen, substituted- or unsubstituted- alkyl, substituted- or 15 unsubstituted- aryl, substituted- or unsubstituted- heteroaryl, substituted- or unsubstituted- cycloalkyl, and substituted- or unsubstituted- heterocyclyl; wherein, the “alkyl", “alkenyl", and “alkynyl" are substituted with 1 to 6 20 substituents selected independently from the group consisting of oxo, 10a 10 1 halogen, nitro, cyano, aryl, hereroaryl, cycloalkyl, R SO -, R A -, 10a 10a 10 10 R OC(=O)-, R C(=O)O-, (R )(H)NC(=O)-, (R )(alkyl)NC(=O)-, 10a 10 10 10 1 R C(=O)N(H)-, (R )(H)N-, (R )(alkyl)N-, (R )(H)NC(=A )N(H)-, and 10 1 (R )(alkyl)NC(=A )N(H)-; 25 the “cycloalkyl" is substituted with 1 to 6 substituents selected independently from the group consisting of oxo, halogen, nitro, cyano, 10a 10a 10 1 aryl, hereroaryl, alkyl, alkenyl, alkynyl, R C(=O)-, R SO -, R A -, 10a 10a 10 10 R OC(=O)-, R C(=O)O-, (R )(H)NC(=O)-, (R )(alkyl)NC(=O)-, 10a 10 10 10 1 R C(=O)N(H)-, (R )(H)N-, (R )(alkyl)N-, (R )(H)NC(=A )N(H)-, and 10 1 30 (R )(alkyl)NC(=A )N(H)-; FPAA2865PCT the "aryl" is substituted with 1 to 3 substituents selected independently from the group consisting of halogen, nitro, cyano, hydroxy, C to C alkyl, C to C alkenyl, C to C alkynyl, C to C cycloalkyl, 3- to 6- 2 6 2 6 3 6 membered heterocycle, C to C perhaloalkyl, alkyl-O-, alkenyl-O-, 5 alkynyl-O-, perhaloalkyl-O-, alkyl-N(alkyl)-, alkyl-N(H)-, H N-, alkyl-SO -, perhaloalkyl-SO -, alkyl-C(=O)N(alkyl)-, alkyl-C(=O)N(H)-, alkyl- N(alkyl)C(=O)-, alkyl-N(H)C(=O)-, H NC(=O)-, alkyl-N(alkyl)SO -, alkyl- N(H)SO -, H NSO -; 2 2 2 the “heterocyclyl" is substituted on ring carbons with 1 to 6 substituents 10 selected independently from the group consisting of oxo, halogen, nitro, 10 1 10a cyano, aryl, hereroaryl, alkyl, alkenyl, alkynyl, R A -, R OC(=O)-, 10a 10 10 10a 10 R C(=O)O-, (R )(H)NC(=O)-, (R )(alkyl)NC(O)-, R C(=O)N(H)-, (R )(H)N- 10 10 1 10 1 , (R )(alkyl)N-, (R )(H)NC(=A )N(H)-, and (R )(alkyl)NC(=A )N(H)-; the “heterocyclyl” is substituted on ring nitrogen(s) with one or more 15 substituents selected from the group consisting of aryl, hereroaryl, alkyl, 10a 10a 10a 10 alkenyl, alkynyl, R C(=O)-, R SO -, R OC(=O)-, (R )(H)NC(=O)-, (R )(alkyl)NC(=O)-; the "heteroaryl" is substituted with 1 to 3 substituents selected independently from the group consisting of halogen, nitro, cyano, 20 hydroxy, C to C alkyl, C to C alkenyl, C to C alkynyl, C to C 1 6 2 6 2 6 3 6 cycloalkyl, 3- to 6- membered heterocycle, C to C perhaloalkyl, alkyl-O-, alkenyl-O-, alkynyl-O-, perhaloalkyl-O-, alkyl-N(alkyl)-, alkyl-N(H)-, H N-, alkyl-SO -, perhaloalkyl-SO -, alkyl-C(=O)N(alkyl)-, alkyl-C(=O)N(H)-, alkyl-N(alkyl)C(=O)-, alkyl-N(H)C(=O)-, H NC(=O)-, alkyl-N(alkyl)SO -, and 25 alkyl-N(H)SO -, H NSO -; 2 2 2 the “3- to 10- membered heterocyclic ring” is substituted with 1 to 3 substituents selected from the group consisting of oxo, halogen, nitro, 10a 10a cyano, aryl, hereroaryl, alkyl, alkenyl, alkynyl, R C(=O)-, R SO -, 10 1 10a 10a 10 10 R A -, R OC(=O)-, R C(=O)O-, (R )(H)NC(=O)-, (R )(alkyl)NC(=O)-, 10a 10 10 10 1 30 R C(=O)N(H)-, (R )(H)N-, (R )(alkyl)N-, (R )(H)NC(=A )N(H)-, and 10 1 (R )(alkyl)NC(=A )N(H)-; FPAA2865PCT wherein, A is selected from the group consisting of O and S; R is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and 5 R is selected from the group consisting of alkyl, alkenyl, alkynyl, perhaloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl.
2. The compound of formula I, its tautomeric forms, its stereoisomers, its sulfoxides, its N-oxides, its pharmaceutically acceptable salts, its 10 polymorphs, its solvates, its optical isomers, its clathrates or its co- crystals, as claimed in claim 1, wherein R is selected as substituted- or unsubstituted- alkyl.
3. The compound of formula I, its tautomeric forms, its stereoisomers, its 15 sulfoxides, its N-oxides, its pharmaceutically acceptable salts, its polymorphs, its solvates, its optical isomers, its clathrates or its co- crystals, as claimed in any one of claims 1 or 2, wherein R is selected as substituted- or unsubstituted- alkyl. 20
4. The compound of formula I, its tautomeric forms, its stereoisomers, its sulfoxides, its N-oxides, its pharmaceutically acceptable salts, its polymorphs, its solvates, its optical isomers, its clathrates or its co- crystals, as claimed in any one of claims 1-3, wherein R is selected substituted- or unsubstituted- alkyl.
5. The compound of formula I, its tautomeric forms, its stereoisomers, its sulfoxides, its N-oxides, its pharmaceutically acceptable salts, its polymorphs, its solvates, its optical isomers, its clathrates or its co- crystals, as claimed in any one of claims 1-4, wherein R is selected as 30 substituted- or unsubstituted- aryl. FPAA2865PCT
6. The compound of formula I, its tautomeric forms, its stereoisomers, its sulfoxides, its N-oxides, its pharmaceutically acceptable salts, its polymorphs, its solvates, its optical isomers, its clathrates or its co- crystals, as claimed in any one of claims 1-5, wherein ‘a’ is selected as 0.
7. The compound of formula I, its tautomeric forms, its stereoisomers, its sulfoxides, its N-oxides, its pharmaceutically acceptable salts, its polymorphs, its solvates, its optical isomers, its clathrates or its co- crystals, as claimed in any one of claims 1-6, wherein R is selected as 10 substituted- or unsubstituted- alkyl; R is selected as substituted- or unsubstituted- alkyl; R is selected substituted- or unsubstituted- alkyl; R is selected as substituted- or unsubstituted- aryl; and ‘a’ is selected as 15
8. The compound of formula I, its tautomeric forms, its stereoisomers, its sulfoxides, its N-oxides, its pharmaceutically acceptable salts, its polymorphs, its solvates, its optical isomers, its clathrates or its co- crystals, as claimed in any one of claims 1-7, wherein the compound is selected from- 4-(2-(4-chlorophenyl)-3,5-dimethylpropionyl-1H-pyrrolyl) benzenesulfonamide; and 4-(2-(4-chlorophenyl)ethylmethylpropionyl-1H-pyrrol 25 yl)benzenesulfonamide.
9. A pharmaceutical composition comprising a compound of any one of claims 1-8 and a pharmaceutically acceptable carrier. 30 10. Use of a compound of formula I, its tautomeric forms, its stereoisomers, its sulfoxides, its N-oxides, its pharmaceutically acceptable salts, its polymorphs, its solvates, its optical isomers, its clathrates or its co- FPAA2865PCT crystals, in the preparation of a medicament for treating a disease or disorder or condition, [ ] SO NH (I) 2 2 5 wherein, R is selected from the group consisting of hydrogen, halogen, substituted- or unsubstituted- alkyl, substituted- or unsubstituted- alkenyl, substituted- or unsubstituted- alkynyl, perhaloalkyl, and substituted- or unsubstituted- cycloalkyl; 10 R is selected from the group consisting of substituted- or unsubstituted- 6 7 6 7a 6a alkyl, (R )(R )N-, (R )N(OR )-, and R O-; R is selected from the group consisting of substituted- or unsubstituted- alkyl, substituted- or unsubstituted- alkenyl, substituted- or unsubstituted- alkynyl, substituted- or unsubstituted- cycloalkyl; 15 R is selected from the group consisting of substituted- or unsubstituted- aryl, substituted- or unsubstituted- heteroaryl; 5 5 5 [R ] is ‘a’ times repetition of ‘R ’ groups, each R is independently selected from the group consisting of halo, substituted- or unsubstituted- alkyl, R O-; ‘a’ is an integer selected from 0, 1, and 2; 20 wherein, R and R are independently selected from hydrogen, substituted- or unsubstituted- alkyl, R C(=O)-, R SO -; such that when 2 6 7 6 7 R is (R )(R )N-, R and R together with the nitrogen atom to which they FPAA2865PCT are attached may form a 3 to 10 member substituted- or unsubstituted- heterocycle containing one to three hetero atoms/groups selected from the group consisting of S, N, O the said heterocycle may be saturated or unsaturated, monocyclic or bicyclic or spiro, or the said heterocycle may 5 contain an alkylene bridge; R is selected from hydrogen and substituted- or unsubstituted- alkyl; R is selected as substituted- or unsubstituted- alkyl; wherein R is selected from hydrogen, substituted- or unsubstituted- alkyl, and perhaloalkyl; 10 wherein, R is independently selected from the group consisting of hydrogen, substituted- or unsubstituted- alkyl, substituted- or unsubstituted- aryl, substituted- or unsubstituted- heteroaryl, substituted- or unsubstituted- cycloalkyl, and substituted- or unsubstituted- heterocyclyl; 15 wherein, the “alkyl", “alkenyl", and “alkynyl" are substituted with 1 to 6 substituents selected independently from the group consisting of oxo, 10a 10 1 halogen, nitro, cyano, aryl, hereroaryl, cycloalkyl, R SO2-, R A -, 10a 10a 10 10 R OC(=O)-, R C(=O)O-, (R )(H)NC(=O)-, (R )(alkyl)NC(=O)-, 10a 10 10 10 1 20 R C(=O)N(H)-, (R )(H)N-, (R )(alkyl)N-, (R )(H)NC(=A )N(H)-, and 10 1 (R )(alkyl)NC(=A )N(H)-; the “cycloalkyl" is substituted with 1 to 6 substituents selected independently from the group consisting of oxo, halogen, nitro, cyano, 10a 10a 10 1 aryl, hereroaryl, alkyl, alkenyl, alkynyl, R C(=O)-, R SO -, R A -, 10a 10a 10 10 25 R OC(=O)-, R C(=O)O-, (R )(H)NC(=O)-, (R )(alkyl)NC(=O)-, 10a 10 10 10 1 R C(=O)N(H)-, (R )(H)N-, (R )(alkyl)N-, (R )(H)NC(=A )N(H)-, and 10 1 (R )(alkyl)NC(=A )N(H)-; the "aryl" is substituted with 1 to 3 substituents selected independently from the group consisting of halogen, nitro, cyano, hydroxy, C1 to C6 30 alkyl, C to C alkenyl, C to C alkynyl, C to C cycloalkyl, 3- to 6- 2 6 2 6 3 6 FPAA2865PCT membered heterocycle, C to C perhaloalkyl, alkyl-O-, alkenyl-O-, alkynyl-O-, perhaloalkyl-O-, alkyl-N(alkyl)-, alkyl-N(H)-, H N-, alkyl-SO -, perhaloalkyl-SO -, alkyl-C(=O)N(alkyl)-, alkyl-C(=O)N(H)-, alkyl- N(alkyl)C(=O)-, alkyl-N(H)C(=O)-, H NC(=O)-, alkyl-N(alkyl)SO -, alkyl- 5 N(H)SO -, H NSO -; 2 2 2 the “heterocyclyl" is substituted on ring carbons with 1 to 6 substituents selected independently from the group consisting of oxo, halogen, nitro, 10 1 10a cyano, aryl, hereroaryl, alkyl, alkenyl, alkynyl, R A -, R OC(=O)-, 10a 10 10 10a 10 R C(=O)O-, (R )(H)NC(=O)-, (R )(alkyl)NC(O)-, R C(=O)N(H)-, (R )(H)N- 10 10 1 10 1 10 , (R )(alkyl)N-, (R )(H)NC(=A )N(H)-, and (R )(alkyl)NC(=A )N(H)-; the “heterocyclyl” is substituted on ring nitrogen(s) with one or more substituents selected from the group consisting of aryl, hereroaryl, alkyl, 10a 10a 10a 10 alkenyl, alkynyl, R C(=O)-, R SO -, R OC(=O)-, (R )(H)NC(=O)-, (R )(alkyl)NC(=O)-; 15 the "heteroaryl" is substituted with 1 to 3 substituents selected independently from the group consisting of halogen, nitro, cyano, hydroxy, C to C alkyl, C to C alkenyl, C to C alkynyl, C to C 1 6 2 6 2 6 3 6 cycloalkyl, 3- to 6- membered heterocycle, C1 to C6 perhaloalkyl, alkyl-O-, alkenyl-O-, alkynyl-O-, perhaloalkyl-O-, alkyl-N(alkyl)-, alkyl-N(H)-, H N-, 20 alkyl-SO -, perhaloalkyl-SO -, alkyl-C(=O)N(alkyl)-, alkyl-C(=O)N(H)-, alkyl-N(alkyl)C(=O)-, alkyl-N(H)C(=O)-, H NC(=O)-, alkyl-N(alkyl)SO -, and alkyl-N(H)SO -, H NSO -; 2 2 2 the “3- to 10- membered heterocyclic ring” is substituted with 1 to 3 substituents selected from the group consisting of oxo, halogen, nitro, 10a 10a 25 cyano, aryl, hereroaryl, alkyl, alkenyl, alkynyl, R C(=O)-, R SO -, 10 1 10a 10a 10 10 R A -, R OC(=O)-, R C(=O)O-, (R )(H)NC(=O)-, (R )(alkyl)NC(=O)-, 10a 10 10 10 1 R C(=O)N(H)-, (R )(H)N-, (R )(alkyl)N-, (R )(H)NC(=A )N(H)-, and
10 1 (R )(alkyl)NC(=A )N(H)-; wherein, 30 A is selected from the group consisting of O and S; FPAA2865PCT R is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and R is selected from the group consisting of alkyl, alkenyl, alkynyl, perhaloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl.
11. The use as claimed in claim 10, wherein the medicament is for preventing or treating a disease or its symptoms or a disorder mediated partially or completely by nicotinic acetylcholine receptors. 10
12. The use as claimed in claim 10, wherein the disease or disorder or condition is selected from the group classified or diagnosed as major or minor neurocognitive disorders, or disorders arising due to neurodegeneration. 15
13. The use as claimed in claim 10, wherein the medicament is for use in combination with or as adjunct to medications utilized in the treatment of attention deficit hyperactivity disorders, schizophrenia, cognitive disorders, Alzheimer's disease, Parkinson’s dementia, vascular dementia or dementia associated with Lewy bodies, and traumatic brain injury.
14. The use as claimed in claim 10, wherein the medicament is for use in combination with or as an adjunct to acetylcholinesterase inhibitors, disease modifying drugs or biologics for neurodegenerative disorders, dopaminergic drugs, antidepressants, or a typical or atypical 25 antipsychotic.
15. A compound as claimed in claim 1 substantially as herein described with reference to any example thereof. 30
16. A pharmaceutical composition as claimed in claim 9 substantially as herein described with reference to any example thereof. FPAA2865PCT
17. A use as claimed in claim 10 substantially as herein described with reference to any example thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN458KO2011 | 2011-03-31 | ||
IN458/KOL/2011 | 2011-03-31 | ||
PCT/IB2012/051451 WO2012131576A1 (en) | 2011-03-31 | 2012-03-27 | Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ615583A NZ615583A (en) | 2015-09-25 |
NZ615583B2 true NZ615583B2 (en) | 2016-01-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012235779B2 (en) | Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as Alzheimer's and Parkinson's disease | |
EP2729455B1 (en) | Biaryl derivatives as nachr modulators | |
EP2678327B9 (en) | Heteroaryl derivatives as alpha7 nachr modulators | |
US9617210B2 (en) | Pyrrole derivatives as alpha 7 NACHR modulators | |
US9388196B2 (en) | Thiazole derivatives as alpha 7 nAChR modulators | |
US9504680B2 (en) | Pyrrole derivatives as alpha 7 nAChR modulators | |
EP2945941B1 (en) | Pyrrole derivatives as alpha 7 nachr modulators | |
NZ615583B2 (en) | Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease | |
NZ615001B2 (en) | Heteroaryl derivatives as alpha7 nachr modulators |